Block	O
of	O
granulocytic	O
differentiation	O
of	O
32Dcl3	B-cell_line
cells	I-cell_line
by	O
AML1/ETO	B-DNA
(	I-DNA
MTG8	I-DNA
)	I-DNA
but	O
not	O
by	O
highly	O
expressed	O
Bcl-2	B-protein
.	O

The	O
chimeric	B-DNA
gene	I-DNA
,	I-DNA
AML1/ETO	B-DNA
(	I-DNA
MTG8	I-DNA
)	I-DNA
,	O
generated	O
in	O
t	B-DNA
(	I-DNA
8	I-DNA
;	I-DNA
21	I-DNA
)	I-DNA
acute	O
myeloid	O
leukemia	O
enhances	O
the	O
expression	O
of	O
Bcl-2	B-protein
.	O

To	O
evaluate	O
whether	O
this	O
enhancement	O
is	O
the	O
primary	O
role	O
of	O
AML1/ETO	B-DNA
in	O
leukemogenesis	O
,	O
effects	O
of	O
over-expression	O
of	O
Bcl-2	B-protein
in	O
the	O
murine	B-cell_line
myeloid	I-cell_line
precursor	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
32Dcl3	B-cell_line
,	O
were	O
examined	O
.	O

When	O
32Dcl3	B-cell_line
cells	I-cell_line
expressing	O
exogenous	O
Bcl-2	B-protein
were	O
induced	O
to	O
differentiate	O
,	O
the	O
onset	O
of	O
morphological	O
differentiation	O
was	O
delayed	O
.	O

However	O
,	O
even	O
the	O
cells	O
expressing	O
very	O
high	O
levels	O
of	O
exogenous	O
Bcl-2	B-protein
eventually	O
underwent	O
differentiation	O
without	O
a	O
significant	O
decrease	O
in	O
the	O
synthesis	O
of	O
Bcl-2	B-protein
.	O

On	O
the	O
contrary	O
,	O
32Dcl3	B-cell_line
cells	I-cell_line
stably	O
expressing	O
AML1/ETO	B-DNA
were	O
completely	O
resistant	O
to	O
differentiation	O
and	O
continued	O
to	O
grow	O
in	O
the	O
presence	O
of	O
G-CSF	B-protein
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
interpretation	O
that	O
stimulation	O
of	O
Bcl-2	B-protein
expression	O
is	O
not	O
the	O
primary	O
target	O
of	O
AML1/ETO	B-DNA
.	O

Oncogene	NULL
(	NULL
1999	NULL
)	NULL
18	NULL
,	NULL
4055-4062	NULL
©	NULL
1999	NULL
Stockton	NULL
Press	NULL
All	NULL
rights	NULL
reserved	NULL
0950-9232/99	NULL
$	NULL
12.00	NULL
http	NULL
:	NULL
//www	NULL
.	NULL

stockton-press.co.uk/onc	NULL
Block	NULL
of	NULL
granulocytic	NULL
differentiation	NULL
of	NULL
32Dcl3	NULL
cells	NULL
by	NULL
AML1/	NULL
ETO	NULL
(	NULL
MTGS8	NULL
)	NULL
but	NULL
not	NULL
by	NULL
highly	NULL
expressed	NULL
Bcl-2	NULL
Hidetsugu	NULL
Kohzaki	NULL
'	NULL
,	NULL
Kosei	NULL
Ito	NULL
'	NULL
,	NULL
Gang	NULL
Huang	NULL
'	NULL
,	NULL
Hee-Jun	NULL
Wee	NULL
'	NULL
,	NULL
Yota	NULL
Murakami	NULL
'	NULL
and	NULL
Yoshiaki	NULL
Ito*	NULL
'	NULL
'Department	NULL
of	NULL
Viral	NULL
Oncology	NULL
,	NULL
Institute	NULL
for	NULL
Virus	NULL
Research	NULL
,	NULL
Kyoto	NULL
University	NULL
,	NULL
Shogoin	NULL
,	NULL
Sakyo-ku	NULL
,	NULL
Kyoto	NULL
606-8507	NULL
,	NULL
Japan	NULL
The	NULL
chimeric	NULL
gene	NULL
,	NULL
AML1/ETO	NULL
(	NULL
MTG8	NULL
)	NULL
,	NULL
generated	NULL
in	NULL
t	NULL
(	NULL
8	NULL
;	NULL
21	NULL
)	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
enhances	NULL
the	NULL
expression	NULL
of	NULL
Bcl-2	NULL
.	NULL

To	NULL
evaluate	NULL
whether	NULL
this	NULL
enhancement	NULL
is	NULL
the	NULL
primary	NULL
role	NULL
of	NULL
AML1/ETO	NULL
in	NULL
leukemogenesis	NULL
,	NULL
effects	NULL
of	NULL
over-expression	NULL
of	NULL
Bcl-2	NULL
in	NULL
the	NULL
murine	NULL
myeloid	NULL
precursor	NULL
cell	NULL
line	NULL
,	NULL
32Dcl3	NULL
,	NULL
were	NULL
examined	NULL
.	NULL

When	NULL
32Dcl3	NULL
cells	NULL
expressing	NULL
exogenous	NULL
Bcl-2	NULL
were	NULL
induced	NULL
to	NULL
differentiate	NULL
,	NULL
the	NULL
onset	NULL
of	NULL
morphological	NULL
differentiation	NULL
was	NULL
delayed	NULL
.	NULL

However	NULL
,	NULL
even	NULL
the	NULL
cells	NULL
expressing	NULL
very	NULL
high	NULL
levels	NULL
of	NULL
exogenous	NULL
Bcl-2	NULL
eventually	NULL
underwent	NULL
differentiation	NULL
without	NULL
a	NULL
significant	NULL
decrease	NULL
in	NULL
the	NULL
synthesis	NULL
of	NULL
Bcl-2	NULL
.	NULL

On	NULL
the	NULL
contrary	NULL
,	NULL
32Dcl3	NULL
cells	NULL
stably	NULL
expressing	NULL
AMLI/ETO	NULL
were	NULL
completely	NULL
resistant	NULL
to	NULL
differentiation	NULL
and	NULL
continued	NULL
to	NULL
grow	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
G-CSF	NULL
.	NULL

These	NULL
results	NULL
are	NULL
consistent	NULL
with	NULL
the	NULL
interpretation	NULL
that	NULL
stimulation	NULL
of	NULL
Bcl-2	NULL
expression	NULL
is	NULL
not	NULL
the	NULL
primary	NULL
target	NULL
of	NULL
Keywords	NULL
:	NULL
AML1	NULL
;	NULL
AMLI/ETO	NULL
(	NULL
MTG8	NULL
)	NULL
;	NULL
Bel-2	NULL
;	NULL
32Dcl3	NULL
;	NULL
granulocytic	NULL
differentiation	NULL
Introduction	NULL
The	NULL
AMLlI	NULL
gene	NULL
was	NULL
originally	NULL
identified	NULL
at	NULL
the	NULL
breakpoint	NULL
of	NULL
t	NULL
(	NULL
8	NULL
;	NULL
21	NULL
)	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
(	NULL
Miyoshi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
and	NULL
is	NULL
now	NULL
known	NULL
to	NULL
be	NULL
the	NULL
most	NULL
frequent	NULL
target	NULL
of	NULL
chromosome	NULL
translocations	NULL
associated	NULL
with	NULL
human	NULL
leukemia	NULL
including	NULL
t	NULL
(	NULL
3	NULL
;	NULL
21	NULL
)	NULL
and	NULL
t	NULL
(	NULL
12	NULL
;	NULL
21	NULL
)	NULL
(	NULL
Look	NULL
,	NULL
1997	NULL
)	NULL
.	NULL

AML1	NULL
has	NULL
an	NULL
essential	NULL
role	NULL
in	NULL
inducing	NULL
definitive	NULL
hematopoiesis	NULL
and	NULL
plays	NULL
pivotal	NULL
roles	NULL
in	NULL
regulating	NULL
cell	NULL
type	NULL
specific	NULL
genes	NULL
in	NULL
various	NULL
hematopoietic	NULL
cells	NULL
(	NULL
Okuda	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
;	NULL
Wang	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
;	NULL
Sasaki	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
;	NULL
Okada	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

AML1	NULL
,	NULL
also	NULL
called	NULL
polyomavirus	NULL
enhancer	NULL
binding	NULL
protein	NULL
2	NULL
«	NULL
B	NULL
gene	NULL
(	NULL
PEBP2	NULL
«	NULL
B	NULL
)	NULL
or	NULL
core	NULL
binding	NULL
factor	NULL
A2	NULL
gene	NULL
(	NULL
CBFA	NULL
?	NULL
)	NULL

,	NULL
is	NULL
one	NULL
of	NULL
three	NULL
mammalian	NULL
Runt-domain-encoding	NULL
genes	NULL
and	NULL
its	NULL
product	NULL
is	NULL
the	NULL
a	NULL
subunit	NULL
of	NULL
a	NULL
heterodimeric	NULL
transcription	NULL
factor	NULL
PEBP2/CBF	NULL
(	NULL
re-viewed	NULL
by	NULL
Speck	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Ito	NULL
,	NULL
1996	NULL
;	NULL
Ito	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

In	NULL
t	NULL
(	NULL
8	NULL
;	NULL
21	NULL
)	NULL
AML	NULL
,	NULL
the	NULL
N-terminal	NULL
region	NULL
of	NULL
AML1I	NULL
comprising	NULL
the	NULL
Runt	NULL
domain	NULL
,	NULL
a	NULL
highly	NULL
conserved	NULL
region	NULL
required	NULL
for	NULL
DNA	NULL
binding	NULL
and	NULL
heterodimeriza-tion	NULL
with	NULL
the	NULL
B	NULL
subunit	NULL
,	NULL
is	NULL
fused	NULL
to	NULL
ETO	NULL
(	NULL
MTG8	NULL
)	NULL
,	NULL
generating	NULL
the	NULL
AMLI/ETO	NULL
(	NULL
MTG8	NULL
)	NULL
fusion	NULL
gene	NULL
product	NULL
(	NULL
Erickson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Miyoshi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

In	NULL
t	NULL
(	NULL
3	NULL
;	NULL
21	NULL
)	NULL
,	NULL
several	NULL
fusion	NULL
products	NULL
are	NULL
formed	NULL
,	NULL
the	NULL
*Correspondence	NULL
:	NULL
Y	NULL
Ito	NULL
Received	NULL
24	NULL
November	NULL
1998	NULL
;	NULL
revised	NULL
25	NULL
January	NULL
1999	NULL
;	NULL
accepted	NULL
25	NULL
January	NULL
1999	NULL
major	NULL
one	NULL
being	NULL
AMLI/EVI-1	NULL
in	NULL
which	NULL
the	NULL
same	NULL
N-terminal	NULL
region	NULL
of	NULL
AML1	NULL
present	NULL
in	NULL
AMLI/ETO	NULL
is	NULL
fused	NULL
to	NULL
EVI-1	NULL
(	NULL
Nucifora	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
,	NULL
1994	NULL
,	NULL
1995	NULL
;	NULL
Mitani	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
t	NULL
(	NULL
12	NULL
;	NULL
21	NULL
)	NULL
,	NULL
the	NULL
chimeric	NULL
protein	NULL
produced	NULL
,	NULL
termed	NULL
TEL/AML1	NULL
,	NULL
contains	NULL
the	NULL
N-terminal	NULL
half	NULL
of	NULL
a	NULL
member	NULL
of	NULL
the	NULL
Ets	NULL
family	NULL
,	NULL
TEL	NULL
,	NULL
fused	NULL
to	NULL
the	NULL
entire	NULL
AML1I	NULL
on	NULL
the	NULL
C-terminal	NULL
side	NULL
(	NULL
Golub	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Romana	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

All	NULL
of	NULL
these	NULL
chimeric	NULL
proteins	NULL
retain	NULL
the	NULL
Runt	NULL
domain	NULL
of	NULL
AML1	NULL
,	NULL
suggesting	NULL
their	NULL
potential	NULL
ability	NULL
to	NULL
bind	NULL
to	NULL
DNA	NULL
and	NULL
interact	NULL
with	NULL
the	NULL
B	NULL
subunit	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
gene	NULL
encoding	NULL
the	NULL
B	NULL
subunit	NULL
of	NULL
PEBP2	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
chromosome	NULL
anomaly	NULL
associated	NULL
with	NULL
inv	NULL
(	NULL
16	NULL
)	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
(	NULL
Liu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

In	NULL
this	NULL
case	NULL
,	NULL
the	NULL
chimeric	NULL
gene	NULL
,	NULL
B/MYH11	NULL
encoding	NULL
the	NULL
chimeric	NULL
protein	NULL
,	NULL
B/SMMHC	NULL
,	NULL
is	NULL
produced	NULL
.	NULL

B/SMMHC	NULL
contains	NULL
the	NULL
C-terminal	NULL
coiled-coil	NULL
region	NULL
of	NULL
SMMHC	NULL
(	NULL
smooth	NULL
muscle	NULL
myosine	NULL
heavy	NULL
chain	NULL
)	NULL
fused	NULL
to	NULL
the	NULL
C-terminal	NULL
region	NULL
of	NULL
the	NULL
B	NULL
subunit	NULL
protein	NULL
.	NULL

This	NULL
chimeric	NULL
protein	NULL
forms	NULL
a	NULL
dimer	NULL
with	NULL
AML1	NULL
more	NULL
readily	NULL
than	NULL
the	NULL
normal	NULL
B	NULL
subunit	NULL
(	NULL
Lu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Kanno	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

We	NULL
and	NULL
others	NULL
have	NULL
shown	NULL
that	NULL
these	NULL
chimeric	NULL
genes	NULL
strongly	NULL
inhibit	NULL
the	NULL
activity	NULL
of	NULL
a	NULL
variety	NULL
of	NULL
promoters	NULL
through	NULL
the	NULL
PEBP2	NULL
sites	NULL
,	NULL
including	NULL
T	NULL
cell	NULL
receptor	NULL
B	NULL
enhancer/promoter	NULL
(	NULL
Meyers	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
,	NULL
1996	NULL
;	NULL
Tanaka	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Hiebert	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
,	NULL
GM-CSF	NULL
promoter	NULL
(	NULL
Frank	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
,	NULL
IL-3	NULL
promoter	NULL
(	NULL
Uchida	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
,	NULL
M-CSF	NULL
receptor	NULL
promoter	NULL
(	NULL
Fears	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
;	NULL
Kanno	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
and	NULL
Moloney	NULL
murine	NULL
leukemia	NULL
virus	NULL
enhancer	NULL
(	NULL
Liu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
it	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
eight	NULL
out	NULL
of	NULL
160	NULL
patients	NULL
with	NULL
leukemia	NULL
have	NULL
point	NULL
mutations	NULL
in	NULL
AML1	NULL
.	NULL

These	NULL
mutations	NULL
are	NULL
all	NULL
clustered	NULL
in	NULL
the	NULL
Runt	NULL
domain	NULL
.	NULL

Three	NULL
heterozygous	NULL
mutants	NULL
of	NULL
AML1	NULL
show	NULL
neither	NULL
DNA	NULL
binding	NULL
nor	NULL
transactivation	NULL
.	NULL

These	NULL
loss-of-function	NULL
mutations	NULL
may	NULL
be	NULL
related	NULL
to	NULL
predisposition	NULL
to	NULL
,	NULL
or	NULL
the	NULL
progression	NULL
of	NULL
leukemia	NULL
.	NULL

In	NULL
two	NULL
other	NULL
cases	NULL
,	NULL
biallelic	NULL
nonsense	NULL
mutants	NULL
were	NULL
found	NULL
which	NULL
encode	NULL
AML1	NULL
truncated	NULL
within	NULL
the	NULL
Runt	NULL
domain	NULL
.	NULL

In	NULL
these	NULL
two	NULL
cases	NULL
,	NULL
essentially	NULL
all	NULL
of	NULL
the	NULL
AMLI	NULL
function	NULL
was	NULL
destroyed	NULL
(	NULL
Osato	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
)	NULL
.	NULL

These	NULL
results	NULL
coupled	NULL
with	NULL
the	NULL
observations	NULL
mentioned	NULL
above	NULL
that	NULL
chimeric	NULL
genes	NULL
involving	NULL
AML1	NULL
or	NULL
the	NULL
B	NULL
subunit	NULL
gene	NULL
strongly	NULL
inhibit	NULL
transcription	NULL
lead	NULL
to	NULL
a	NULL
hypothesis	NULL
that	NULL
a	NULL
loss	NULL
of	NULL
AML1	NULL
function	NULL
at	NULL
appropriate	NULL
stage	NULL
of	NULL
myeloid	NULL
cell	NULL
development	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
leukemogenesis	NULL
.	NULL

In	NULL
contradiction	NULL
of	NULL
the	NULL
above	NULL
hypothesis	NULL
,	NULL
Bcl-2	NULL
(	NULL
Klampfer	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
and	NULL
macrophage	NULL
colony	NULL
stimulation	NULL
factor	NULL
(	NULL
M-CSF	NULL
)	NULL
receptor	NULL
promoters	NULL
(	NULL
Rhoades	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
are	NULL
upregulated	NULL
by	NULL
AMLI/	NULL
ETO	NULL
.	NULL

A	NULL
PEBP2	NULL
binding	NULL
site	NULL
has	NULL
been	NULL
identified	NULL
in	NULL
the	NULL
5	NULL
untranslated	NULL
region	NULL
of	NULL
the	NULL
Bel-2	NULL
gene	NULL
,	NULL
and	NULL
AMLI1/	NULL
ETO	NULL
,	NULL
but	NULL
not	NULL
AML1	NULL
or	NULL
ETO	NULL
,	NULL
activates	NULL
transcription	NULL
of	NULL
Bcel-2	NULL
(	NULL
Klampfer	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

The	NULL
Bcl-2	NULL
gene	NULL
was	NULL
Inability	NULL
of	NULL
Bcl-2	NULL
to	NULL
block	NULL
differentiation	NULL
of	NULL
32DcI13	NULL
H	NULL
Kohzaki	NULL
et	NULL
al	NULL
4056	NULL
first	NULL
identified	NULL
at	NULL
the	NULL
breakpoint	NULL
of	NULL
t	NULL
(	NULL
14	NULL
;	NULL
18	NULL
)	NULL
follicular	NULL
lymphoma	NULL
(	NULL
Bakhshi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
;	NULL
Cleary	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
;	NULL
Tsujimoto	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
)	NULL
.	NULL

Numerous	NULL
studies	NULL
have	NULL
demonstrated	NULL
the	NULL
ability	NULL
of	NULL
Bel-2	NULL
to	NULL
protect	NULL
cells	NULL
of	NULL
lymphoid	NULL
,	NULL
myeloid	NULL
and	NULL
neuronal	NULL
lineages	NULL
from	NULL
apoptosis	NULL
(	NULL
Reed	NULL
,	NULL
1994	NULL
)	NULL
.	NULL

Genes	NULL
that	NULL
regulate	NULL
cell	NULL
death	NULL
are	NULL
potentially	NULL
important	NULL
targets	NULL
for	NULL
leukemogenic	NULL
chimeric	NULL
transcription	NULL
factors	NULL
.	NULL

AML1I/ETO	NULL
(	NULL
MTG8	NULL
)	NULL
blocks	NULL
differentiation	NULL
of	NULL
Kasumi-1	NULL
cells	NULL
harboring	NULL
t	NULL
(	NULL
8	NULL
;	NULL
21	NULL
)	NULL
obtained	NULL
from	NULL
an	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
patient	NULL
(	NULL
Asou	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

A	NULL
similar	NULL
differentiation	NULL
block	NULL
can	NULL
be	NULL
observed	NULL
in	NULL
the	NULL
murine	NULL
myeloid	NULL
progenitor	NULL
cell	NULL
line	NULL
,	NULL
32Dcl3	NULL
(	NULL
Valtieri	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
or	NULL
L-G	NULL
(	NULL
Kinashi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
,	NULL
which	NULL
requires	NULL
interleukin	NULL
3	NULL
(	NULL
IL-3	NULL
)	NULL
for	NULL
growth	NULL
and	NULL
undergoes	NULL
granulocytic	NULL
differentiation	NULL
when	NULL
IL-3	NULL
is	NULL
replaced	NULL
by	NULL
G-CSF	NULL
.	NULL

Stable	NULL
expression	NULL
of	NULL
AMLI/ETO	NULL
or	NULL
AML1/	NULL
EVI-1	NULL
prevent	NULL
G-CSF-induced	NULL
granulocytic	NULL
differentiation	NULL
in	NULL
32Dcl3	NULL
(	NULL
Ahn	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
;	NULL
Tanaka	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
or	NULL
L-G	NULL
cells	NULL
(	NULL
Kitabayashi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

Using	NULL
this	NULL
cell	NULL
system	NULL
,	NULL
we	NULL
evaluated	NULL
whether	NULL
upregulation	NULL
of	NULL
Bcl-2	NULL
by	NULL
AML1I/ETO	NULL
is	NULL
the	NULL
primary	NULL
role	NULL
of	NULL
the	NULL
chimeric	NULL
gene	NULL
in	NULL
gross	NULL
changes	NULL
of	NULL
growth	NULL
and	NULL
differentiation	NULL
properties	NULL
of	NULL
32Dcl3	NULL
cells	NULL
.	NULL

Results	NULL
Elevated	NULL
levels	NULL
of	NULL
Bel-2	NULL
in	NULL
cell	NULL
lines	NULL
carrying	NULL
AML1/	NULL
ETO	NULL
(	NULL
MTG8	NULL
)	NULL
and	NULL
B/SMMHC	NULL
Kasumi-1	NULL
and	NULL
SKNO-1	NULL
cells	NULL
derived	NULL
from	NULL
t	NULL
(	NULL
8	NULL
;	NULL
21	NULL
)	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
patients	NULL
and	NULL
expressing	NULL
AMLI/ETO	NULL
have	NULL
elevated	NULL
levels	NULL
of	NULL
Bel-2	NULL
protein	NULL
compared	NULL
with	NULL
cell	NULL
lines	NULL
obtained	NULL
from	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
patients	NULL
not	NULL
harboring	NULL
AML1/ETO	NULL
(	NULL
Klampfer	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

We	NULL
confirmed	NULL
that	NULL
the	NULL
Kasumi-1	NULL
and	NULL
SKNO-1	NULL
cell	NULL
lines	NULL
synthesized	NULL
elevated	NULL
levels	NULL
of	NULL
Bcel-2	NULL
proteins	NULL
compared	NULL
to	NULL
the	NULL
myelomonocytic	NULL
leukemia	NULL
cell	NULL
line	NULL
,	NULL
U937	NULL
and	NULL
promyelocytic	NULL
leukemia	NULL
cell	NULL
line	NULL
,	NULL
HL-60	NULL
(	NULL
Figure	NULL
1	NULL
)	NULL
.	NULL

ME-1	NULL
cells	NULL
harboring	NULL
inv	NULL
(	NULL
16	NULL
)	NULL
synthesize	NULL
the	NULL
chimeric	NULL
protein	NULL
,	NULL
B/SMMHC	NULL
.	NULL

Like	NULL
AMLI/ETO	NULL
,	NULL
B/SMMHC	NULL
deregulates	NULL
the	NULL
expression	NULL
of	NULL
genes	NULL
which	NULL
are	NULL
the	NULL
target	NULL
of	NULL
AML1	NULL
(	NULL
Liu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Kanno	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Figure	NULL
1	NULL
,	NULL
ME-1	NULL
cells	NULL
also	NULL
express	NULL
elevated	NULL
levels	NULL
of	NULL
Bel-2	NULL
compared	NULL
with	NULL
U937	NULL
and	NULL
K562	NULL
cells	NULL
.	NULL

Rapid	NULL
decrease	NULL
of	NULL
Bel-2	NULL
levels	NULL
in	NULL
32DcIl3	NULL
cells	NULL
undergoing	NULL
granulocytic	NULL
differentiation	NULL
The	NULL
murine	NULL
myeloid	NULL
progenitor	NULL
cell	NULL
line	NULL
,	NULL
32Dcl3	NULL
,	NULL
requires	NULL
IL-3	NULL
for	NULL
growth	NULL
.	NULL

32Dcl3	NULL
cells	NULL
continue	NULL
to	NULL
grow	NULL
for	NULL
about	NULL
6	NULL
days	NULL
after	NULL
replacement	NULL
of	NULL
IL-3	NULL
with	NULL
G-CSF	NULL
,	NULL
then	NULL
undergo	NULL
gross	NULL
morphological	NULL
differentiation	NULL
on	NULL
,	NULL
or	NULL
around	NULL
day	NULL
7	NULL
and	NULL
thereafter	NULL
gradually	NULL
lose	NULL
viability	NULL
under	NULL
the	NULL
conditions	NULL
used	NULL
(	NULL
Figure	NULL
2A	NULL
)	NULL
.	NULL

In	NULL
32Dcl3	NULL
cells	NULL
,	NULL
Bcel-2	NULL
protein	NULL
was	NULL
expressed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
IL-3	NULL
but	NULL
the	NULL
level	NULL
of	NULL
expression	NULL
decreased	NULL
rapidly	NULL
after	NULL
replacing	NULL
IL-3	NULL
with	NULL
G-CSF	NULL
(	NULL
Figure	NULL
2B	NULL
)	NULL
.	NULL

On	NULL
day	NULL
4	NULL
in	NULL
the	NULL
G-CSF	NULL
containing	NULL
medium	NULL
,	NULL
Bcl-2	NULL
protein	NULL
became	NULL
undetectable	NULL
.	NULL

At	NULL
this	NULL
time	NULL
point	NULL
,	NULL
cells	NULL
still	NULL
did	NULL
not	NULL
show	NULL
any	NULL
morphological	NULL
changes	NULL
.	NULL

We	NULL
and	NULL
others	NULL
have	NULL
shown	NULL
that	NULL
AMLI/ETO	NULL
blocks	NULL
differentiation	NULL
of	NULL
32Dcl3	NULL
cells	NULL
induced	NULL
by	NULL
G-CSF	NULL
(	NULL
Ahn	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
;	NULL
Kitabayashi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

We	NULL
confirmed	NULL
the	NULL
observation	NULL
:	NULL
32Dc13	NULL
cells	NULL
stably	NULL
expressing	NULL
AML1/	NULL
ETO	NULL
continue	NULL
to	NULL
grow	NULL
up	NULL
to	NULL
10	NULL
days	NULL
even	NULL
after	NULL
IL-3	NULL
was	NULL
replaced	NULL
with	NULL
G-CSF	NULL
(	NULL
Figure	NULL
2A	NULL
)	NULL
.	NULL

Under	NULL
such	NULL
conditions	NULL
,	NULL
the	NULL
level	NULL
of	NULL
the	NULL
Bel-2	NULL
expression	NULL
was	NULL
maintained	NULL
at	NULL
the	NULL
level	NULL
observed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
IL-3	NULL
(	NULL
Figure	NULL
2C	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
exogenous	NULL
Bel-2	NULL
increases	NULL
survival	NULL
of	NULL
32Dcl3	NULL
cells	NULL
The	NULL
rapid	NULL
decrease	NULL
of	NULL
Bel-2	NULL
levels	NULL
during	NULL
granulocytic	NULL
differentiation	NULL
and	NULL
the	NULL
unaltered	NULL
expression	NULL
of	NULL
Bcl-2	NULL
in	NULL
the	NULL
cells	NULL
stably	NULL
expressing	NULL
AMLI/ETO	NULL
even	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
G-CSF	NULL
raised	NULL
the	NULL
possibility	NULL
that	NULL
a	NULL
decrease	NULL
of	NULL
Bel-2	NULL
levels	NULL
is	NULL
a	NULL
prerequisite	NULL
for	NULL
differentiation	NULL
.	NULL

To	NULL
examine	NULL
this	NULL
possibility	NULL
,	NULL
32Dcl3	NULL
cells	NULL
expressing	NULL
exogenous	NULL
murine	NULL
Bcl-2	NULL
from	NULL
a	NULL
constitu-tively	NULL
active	NULL
promoter	NULL
(	NULL
32D-Bcl2	NULL
)	NULL
were	NULL
obtained	NULL
and	NULL
the	NULL
influence	NULL
of	NULL
exogenous	NULL
Bcl-2	NULL
on	NULL
the	NULL
cells	NULL
was	NULL
tested	NULL
.	NULL

Over-expression	NULL
of	NULL
Bel-2	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
delay	NULL
apoptosis	NULL
in	NULL
a	NULL
number	NULL
of	NULL
cytokine-dependent	NULL
cell	NULL
lines	NULL
upon	NULL
cytokine	NULL
deprivation	NULL
(	NULL
Nunez	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Baffy	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Rodel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
and	NULL
to	NULL
mediate	NULL
the	NULL
survival	NULL
signal	NULL
provided	NULL
by	NULL
cytokines	NULL
(	NULL
Lin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
to	NULL
examine	NULL
whether	NULL
expression	NULL
of	NULL
exogenous	NULL
Bcl-2	NULL
can	NULL
prevent	NULL
cell	NULL
death	NULL
,	NULL
32D-Bcl2	NULL
was	NULL
tested	NULL
for	NULL
survival	NULL
after	NULL
removal	NULL
of	NULL
IL-3	NULL
.	NULL

Parental	NULL
32Dcl3	NULL
cells	NULL
rapidly	NULL
lost	NULL
viability	NULL
in	NULL
medium	NULL
containing	NULL
serum	NULL
lacking	NULL
IL-3	NULL
or	NULL
G-CSF	NULL
and	NULL
within	NULL
48	NULL
h	NULL
of	NULL
culture	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IL-3	NULL
most	NULL
of	NULL
the	NULL
cells	NULL
were	NULL
non-viable	NULL
.	NULL

These	NULL
observations	NULL
are	NULL
consistent	NULL
with	NULL
previous	NULL
reports	NULL
(	NULL
Nunez	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Baffy	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Rodel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

On	NULL
the	NULL
contrary	NULL
,	NULL
the	NULL
cell	NULL
number	NULL
of	NULL
32D-Bcl2	NULL
doubled	NULL
after	NULL
the	NULL
removal	NULL
of	NULL
IL-3	NULL
before	NULL
losing	NULL
viability	NULL
,	NULL
and	NULL
about	NULL
50	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
were	NULL
still	NULL
alive	NULL
4.5	NULL
days	NULL
after	NULL
the	NULL
removal	NULL
of	NULL
cytokine	NULL
.	NULL

The	NULL
cells	NULL
that	NULL
Lome	NULL
J	NULL
a	NULL
7	NULL
co	NULL
N	NULL
gam	NULL
3.73	NULL
$	NULL
9	NULL
To	NULL
C	NULL
+4	NULL
mas	NULL
.	NULL

yom	NULL
=	NULL
Eo	NULL
'	NULL
o	NULL
*=	NULL
=	NULL
%	NULL
b	NULL
aA	NULL
a	NULL
z	NULL
P	NULL
&	NULL
&	NULL
©	NULL
6	NULL
I	NULL
0	NULL
¥	NULL
._	NULL
&	NULL
o	NULL
io	NULL
W	NULL
¥	NULL
W	NULL
T	NULL
3	NULL
3	NULL
¥	NULL
a	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
Figure	NULL
1	NULL
-	NULL
Levels	NULL
of	NULL
Bcl-2	NULL
protein	NULL
in	NULL
human	NULL
myeloid	NULL
leukemia	NULL
cell	NULL
lines	NULL
.	NULL

Whole	NULL
cell	NULL
lysates	NULL
from	NULL
Kasumi-1	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
SKNO-1	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
HL-60	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
and	NULL
U937	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
)	NULL
,	NULL
K562	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
and	NULL
ME-1	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
were	NULL
separated	NULL
on	NULL
15	NULL
%	NULL
SDS-PAGE	NULL
.	NULL

Bcl-2	NULL
protein	NULL
was	NULL
detected	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
.	NULL

Levels	NULL
of	NULL
Bel-2	NULL
protein	NULL
relative	NULL
to	NULL
those	NULL
in	NULL
HL60	NULL
were	NULL
as	NULL
follows	NULL
.	NULL

HL-60	NULL
:	NULL
1.0	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
Kasumi-1	NULL
:	NULL
8.7	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
SKNO-1	NULL
:	NULL
13.8	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
U937	NULL
:	NULL
2.2	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
)	NULL
,	NULL
K562	NULL
:	NULL
0.58	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
ME-1	NULL
:	NULL
28.3	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
(	NULL
A	NULL
)	NULL
1010	NULL
O	NULL
109	NULL
€	NULL
32D-AML1/ETO	NULL
Baos	NULL
€	NULL
2	NULL
=107	NULL
&	NULL
32Dcl3	NULL
106	NULL
105	NULL
(	NULL
I	NULL
U	NULL
I	NULL
1	NULL
0	NULL
5	NULL
10	NULL
15	NULL
20	NULL
-	NULL
days	NULL
G-CSF	NULL
(	NULL
B	NULL
)	NULL
(	NULL
C	NULL
)	NULL
G-CSF	NULL
G-CSF	NULL
IL-3	NULL
IL-3	NULL
2	NULL
4	NULL
6	NULL
8	NULL
10	NULL
days	NULL
2	NULL
4	NULL
6	NULL
8	NULL
10	NULL
days	NULL
Figure	NULL
2	NULL
Down-regulation	NULL
of	NULL
Bcl-2	NULL
during	NULL
granulocytic	NULL
differentiation	NULL
of	NULL
32Dc13	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Growth	NULL
curve	NULL
of	NULL
32Dcl3	NULL
and	NULL
32D-AML1/ETO	NULL
in	NULL
response	NULL
to	NULL
G-CSF	NULL
.	NULL

At	NULL
each	NULL
time	NULL
point	NULL
,	NULL
viable	NULL
cells	NULL
excluding	NULL
trypan-blue	NULL
were	NULL
counted	NULL
.	NULL

@	NULL
:	NULL
32Dc13	NULL
,	NULL
O	NULL
:	NULL
32D-AML1/ETO	NULL
.	NULL

(	NULL
B	NULL
)	NULL
and	NULL
(	NULL
C	NULL
)	NULL
Endogenous	NULL
Bel-2	NULL
protein	NULL
in	NULL
32Dcl3	NULL
(	NULL
B	NULL
)	NULL
or	NULL
32D-AMLI/ETO	NULL
(	NULL
C	NULL
)	NULL
,	NULL
respectively	NULL
,	NULL
as	NULL
revealed	NULL
by	NULL
Western	NULL
blotting	NULL
had	NULL
received	NULL
only	NULL
the	NULL
vector	NULL
,	NULL
32D-neo	NULL
,	NULL
behaved	NULL
like	NULL
parental	NULL
cells	NULL
(	NULL
Figure	NULL
3	NULL
)	NULL
.	NULL

The	NULL
level	NULL
of	NULL
expression	NULL
of	NULL
Bel-2	NULL
in	NULL
32D-Bcl2	NULL
was	NULL
about	NULL
7.5	NULL
times	NULL
as	NULL
much	NULL
as	NULL
that	NULL
of	NULL
the	NULL
parental	NULL
cells	NULL
or	NULL
32D-neo	NULL
as	NULL
revealed	NULL
by	NULL
immunoblot	NULL
analysis	NULL
(	NULL
see	NULL
Figure	NULL
4A	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
32Dcl3	NULL
cells	NULL
stably	NULL
expressing	NULL
AML1/	NULL
ETO	NULL
,	NULL
32D-AMLI/ETO	NULL
did	NULL
not	NULL
show	NULL
a	NULL
significant	NULL
increase	NULL
in	NULL
survival	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IL-3	NULL
,	NULL
despite	NULL
the	NULL
fact	NULL
that	NULL
these	NULL
cells	NULL
grew	NULL
continuously	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
G-CSF	NULL
under	NULL
conditions	NULL
that	NULL
induced	NULL
parental	NULL
cell	NULL
differentiation	NULL
(	NULL
Figure	NULL
2A	NULL
)	NULL
.	NULL

Over-expression	NULL
of	NULL
Bel-2	NULL
delays	NULL
differentiation	NULL
of	NULL
32Dcl3	NULL
Next	NULL
,	NULL
the	NULL
influence	NULL
of	NULL
over-expression	NULL
of	NULL
Bcl-2	NULL
on	NULL
differentiation	NULL
was	NULL
examined	NULL
.	NULL

When	NULL
cultured	NULL
in	NULL
IL-3	NULL
containing	NULL
medium	NULL
,	NULL
32D-Bcl2	NULL
maintained	NULL
the	NULL
morphology	NULL
of	NULL
myeloid	NULL
precursor	NULL
cells	NULL
like	NULL
parental	NULL
or	NULL
32D-neo	NULL
cells	NULL
Also	NULL
the	NULL
growth	NULL
rate	NULL
of	NULL
these	NULL
cells	NULL
was	NULL
indistinguishable	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

When	NULL
IL-3	NULL
was	NULL
replaced	NULL
with	NULL
G-CSF	NULL
,	NULL
32D-neo	NULL
cells	NULL
stopped	NULL
growing	NULL
and	NULL
underwent	NULL
differentiation	NULL
around	NULL
day	NULL
8	NULL
like	NULL
parental	NULL
cells	NULL
(	NULL
Figures	NULL
2A	NULL
and	NULL
4B	NULL
)	NULL
.	NULL

On	NULL
the	NULL
contrary	NULL
,	NULL
32D-Bcl2	NULL
continued	NULL
to	NULL
multiply	NULL
beyond	NULL
day	NULL
8	NULL
up	NULL
until	NULL
day	NULL
12	NULL
without	NULL
showing	NULL
any	NULL
sign	NULL
of	NULL
morphological	NULL
differentiation	NULL
.	NULL

Around	NULL
day	NULL
12	NULL
,	NULL
how	NULL
Inability	NULL
of	NULL
Bcl-2	NULL
to	NULL
block	NULL
differentiation	NULL
of	NULL
32DcI13	NULL
H	NULL
Kohzaki	NULL
et	NULL
al	NULL
-	NULL
[	NULL
L	NULL
]	NULL
-	NULL
32Dcl3	NULL
-O-	NULL
32D-Bel2	NULL
-	NULL
@	NULL
-	NULL
32D-neo	NULL
-f-	NULL
32D-AML1/ETO	NULL
200	NULL
_	NULL
150	NULL
P3	NULL
O	NULL
O	NULL
(	NULL
'	NULL
a	NULL
ratio	NULL
of	NULL
viable	NULL
cell	NULL
number	NULL
(	NULL
%	NULL
)	NULL
eal	NULL
&	NULL
1	NULL
O	NULL
|	NULL
0	NULL
1	NULL
2	NULL
3	NULL
4	NULL
50	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
days	NULL
Serum	NULL
(	NULL
+	NULL
)	NULL
,	NULL
IL-3	NULL
(	NULL
-	NULL
)	NULL
,	NULL
G-CSF	NULL
(	NULL
-	NULL
)	NULL
Figure	NULL
3	NULL
-	NULL
Increased	NULL
survival	NULL
of	NULL
32Dcl3	NULL
cells	NULL
expressing	NULL
exogenous	NULL
Bcl-2	NULL
.	NULL

Survival	NULL
of	NULL
32Dc13	NULL
,	NULL
32D-Bcll2	NULL
,	NULL
32D-AMLI/ETO	NULL
and	NULL
32D-neo	NULL
after	NULL
IL-3	NULL
deprivation	NULL
.	NULL

J	NULL
:	NULL
32D¢l3	NULL
,	NULL
O	NULL
:	NULL
32D-Bcl2	NULL
,	NULL
@	NULL
:	NULL
32D-neo	NULL
,	NULL
[	NULL
W	NULL
:	NULL
32D-AML1/ETO	NULL
ever	NULL
,	NULL
32D-Bcl2	NULL
stopped	NULL
growing	NULL
and	NULL
morphological	NULL
differentiation	NULL
became	NULL
evident	NULL
.	NULL

In	NULL
other	NULL
words	NULL
,	NULL
exogenous	NULL
Bcel-2	NULL
delayed	NULL
but	NULL
did	NULL
not	NULL
completely	NULL
block	NULL
granulocytic	NULL
differentiation	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
rate	NULL
of	NULL
decrease	NULL
of	NULL
the	NULL
viable	NULL
cell	NULL
number	NULL
was	NULL
significantly	NULL
lower	NULL
than	NULL
that	NULL
of	NULL
32D-neo	NULL
,	NULL
consistent	NULL
with	NULL
the	NULL
increase	NULL
in	NULL
the	NULL
survival	NULL
rate	NULL
of	NULL
these	NULL
cells	NULL
described	NULL
above	NULL
(	NULL
Figure	NULL
3	NULL
)	NULL
.	NULL

It	NULL
is	NULL
important	NULL
to	NULL
note	NULL
that	NULL
the	NULL
high	NULL
levels	NULL
of	NULL
Bcl-2	NULL
expression	NULL
from	NULL
the	NULL
exogenously	NULL
introduced	NULL
constitutive	NULL
promoter	NULL
were	NULL
maintained	NULL
in	NULL
32D-Bcel2	NULL
throughout	NULL
the	NULL
period	NULL
examined	NULL
,	NULL
even	NULL
after	NULL
morphological	NULL
differentiation	NULL
became	NULL
evident	NULL
and	NULL
viability	NULL
of	NULL
the	NULL
cells	NULL
declined	NULL
(	NULL
Figure	NULL
4C	NULL
)	NULL
.	NULL

This	NULL
is	NULL
in	NULL
contrast	NULL
to	NULL
32D-neo	NULL
in	NULL
which	NULL
Bcl-2	NULL
was	NULL
no	NULL
longer	NULL
detectable	NULL
on	NULL
day	NULL
6	NULL
(	NULL
Figure	NULL
4C	NULL
)	NULL
.	NULL

Since	NULL
the	NULL
results	NULL
shown	NULL
in	NULL
Figure	NULL
4A	NULL
,	NULL
B	NULL
and	NULL
C	NULL
were	NULL
obtained	NULL
with	NULL
a	NULL
population	NULL
of	NULL
cells	NULL
expressing	NULL
Bel-2	NULL
at	NULL
different	NULL
levels	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
effect	NULL
of	NULL
exogenous	NULL
Bcl-2	NULL
more	NULL
precisely	NULL
using	NULL
individual	NULL
cell	NULL
clones	NULL
obtained	NULL
from	NULL
these	NULL
cell	NULL
cultures	NULL
.	NULL

Levels	NULL
of	NULL
expression	NULL
of	NULL
Bcel-2	NULL
in	NULL
independent	NULL
clones	NULL
varied	NULL
widely	NULL
as	NULL
revealed	NULL
by	NULL
Western	NULL
blotting	NULL
(	NULL
Figure	NULL
4D	NULL
)	NULL
.	NULL

We	NULL
chose	NULL
clone	NULL
20	NULL
(	NULL
cl-20	NULL
)	NULL
,	NULL
clone	NULL
6	NULL
(	NULL
cl-6	NULL
)	NULL
and	NULL
clone	NULL
9	NULL
(	NULL
cl-9	NULL
)	NULL
as	NULL
low-	NULL
,	NULL
moderate-	NULL
and	NULL
high-level	NULL
expressors	NULL
of	NULL
Bcl-2	NULL
respectively	NULL
.	NULL

Relative	NULL
levels	NULL
of	NULL
expression	NULL
of	NULL
Bcl-2	NULL
in	NULL
cl-20	NULL
,	NULL
cl-6	NULL
,	NULL
cl-9	NULL
and	NULL
the	NULL
parent	NULL
cells	NULL
were	NULL
1.6	NULL
,	NULL
7.4	NULL
,	NULL
9.5	NULL
and	NULL
1.0	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
growth	NULL
curve	NULL
and	NULL
the	NULL
timing	NULL
of	NULL
morphological	NULL
differentiation	NULL
of	NULL
cl-20	NULL
in	NULL
G-CSF	NULL
was	NULL
indistinguishable	NULL
from	NULL
those	NULL
of	NULL
the	NULL
parental	NULL
cells	NULL
.	NULL

cl-6	NULL
and	NULL
cl-9	NULL
,	NULL
on	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
stopped	NULL
growing	NULL
on	NULL
day	NULL
9	NULL
and	NULL
day	NULL
12	NULL
,	NULL
respectively	NULL
(	NULL
Figure	NULL
4E	NULL
)	NULL
and	NULL
underwent	NULL
morphological	NULL
changes	NULL
(	NULL
Figure	NULL
5	NULL
)	NULL
.	NULL

The	NULL
results	NULL
indicated	NULL
a	NULL
correlation	NULL
between	NULL
the	NULL
levels	NULL
of	NULL
Bcl-2	NULL
expression	NULL
,	NULL
the	NULL
timing	NULL
of	NULL
differentiation	NULL
and	NULL
the	NULL
slope	NULL
of	NULL
the	NULL
decrease	NULL
of	NULL
viable	NULL
cell	NULL
number	NULL
after	NULL
differentiation	NULL
.	NULL

In	NULL
other	NULL
words	NULL
,	NULL
the	NULL
higher	NULL
the	NULL
level	NULL
of	NULL
Bel-2	NULL
expressed	NULL
,	NULL
the	NULL
slower	NULL
the	NULL
timing	NULL
of	NULL
differentiation	NULL
and	NULL
the	NULL
less	NULL
steep	NULL
the	NULL
decline	NULL
in	NULL
viable	NULL
cell	NULL
number	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
the	NULL
results	NULL
indicated	NULL
that	NULL
over-expression	NULL
of	NULL
Bel-2	NULL
reduces	NULL
the	NULL
cell	NULL
death	NULL
that	NULL
accompanies	NULL
granulocytic	NULL
differentiation	NULL
4057	NULL
Inability	NULL
of	NULL
Bcl-2	NULL
to	NULL
block	NULL
differentiation	NULL
of	NULL
32DcI13	NULL
H	NULL
Kohzaki	NULL
et	NULL
al	NULL
4058	NULL
(	NULL
A	NULL
)	NULL
(	NULL
B	NULL
)	NULL
(	NULL
C	NULL
)	NULL
108	NULL
to	NULL
G-CSF	NULL
a	NULL
=	NULL
|	NULL
m	NULL
8	NULL
2	NULL
_	NULL
3	NULL
&	NULL
8	NULL
fr	NULL
32D-Bel2	NULL
A	NULL
Q	NULL
Q	NULL
3	NULL
~-5C	NULL
32D-Bci2	NULL
-	NULL
C	NULL
@	NULL
apepec-s-c	NULL
&	NULL
&	NULL
®	NULL
A	NULL
E	NULL
a	NULL
=106	NULL
32D-neo	NULL
Bel-2	NULL
-	NULL
e-	NULL
s	NULL
32D-neo	NULL
-	NULL
>	NULL
®	NULL
-=	NULL
-	NULL
>	NULL
10	NULL
2	NULL
3	NULL
2	NULL
4	NULL
6	NULL
B8	NULL
10	NULL
12	NULL
0	NULL
5	NULL
-	NULL
10	NULL
15	NULL
20	NULL
25	NULL
days	NULL
G-CSF	NULL
(	NULL
days	NULL
)	NULL
(	NULL
D	NULL
)	NULL
5	NULL
clone	NULL
number	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
1112	NULL
13	NULL
14151617	NULL
181920	NULL
§	NULL
Bel-2	NULL
-	NULL
--	NULL
a	NULL
-angpan	NULL
o	NULL
--	NULL
--	NULL
<	NULL
--	NULL
--	NULL
«	NULL
Dame	NULL
(	NULL
E	NULL
)	NULL
(	NULL
F	NULL
)	NULL
109	NULL
cl-9	NULL
_	NULL
108	NULL
€	NULL
5	NULL
cl-9	NULL
-	NULL
-Bel-2	NULL
€	NULL
§	NULL
107	NULL
2	NULL
cl-6	NULL
e	NULL
iy	NULL
}	NULL
<	NULL
.	NULL

0	NULL
cl-20	NULL
-	NULL
l	NULL
5	NULL
-Bcl-2	NULL
106	NULL
.	NULL

cl-20	NULL
rays	NULL
esa	NULL
ot	NULL
2	NULL
4	NULL
6	NULL
8	NULL
10	NULL
12	NULL
14	NULL
16	NULL
days	NULL
105	NULL
[	NULL
|-	NULL
7	NULL
A	NULL
0	NULL
10	NULL
20	NULL
30	NULL
G-CSF	NULL
(	NULL
days	NULL
)	NULL
Figure	NULL
4	NULL
Effect	NULL
of	NULL
over-expressed	NULL
Bcl-2	NULL
protein	NULL
on	NULL
the	NULL
growth	NULL
and	NULL
differentiation	NULL
of	NULL
32DcI3	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
Bel-2	NULL
protein	NULL
in	NULL
32DcIl3	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
32D-neo	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
and	NULL
32D-Bcl2	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Growth	NULL
curve	NULL
of	NULL
32D-Bcl2	NULL
(	NULL
0	NULL
)	NULL
and	NULL
32D-neo	NULL
(	NULL
@	NULL
)	NULL
in	NULL
response	NULL
to	NULL
G-CSF	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Levels	NULL
of	NULL
Bel-2	NULL
protein	NULL
in	NULL
32D-Bcl2	NULL
(	NULL
upper	NULL
panel	NULL
)	NULL
and	NULL
32D-neo	NULL
(	NULL
lower	NULL
panel	NULL
)	NULL
as	NULL
revealed	NULL
by	NULL
Western	NULL
blotting	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
levels	NULL
of	NULL
Bel-2	NULL
in	NULL
20	NULL
subclones	NULL
of	NULL
32D-Bcl2	NULL
.	NULL

(	NULL
E	NULL
)	NULL
Cell	NULL
growth	NULL
curve	NULL
in	NULL
response	NULL
to	NULL
G-CSF	NULL
of	NULL
three	NULL
subclones	NULL
of	NULL
32D-Bcl2	NULL
,	NULL
c1-6	NULL
,	NULL
cl-9	NULL
and	NULL
cl-20	NULL
,	NULL
expressing	NULL
three	NULL
different	NULL
levels	NULL
of	NULL
Bel-2	NULL
.	NULL

@	NULL
:	NULL
cl-6	NULL
,	NULL
O	NULL
:	NULL
c1-9	NULL
,	NULL
[	NULL
J	NULL
:	NULL
cl-20	NULL
.	NULL

(	NULL
F	NULL
)	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
Bel-2	NULL
expressed	NULL
in	NULL
cl-9	NULL
and	NULL
cl-20	NULL
and	NULL
enhances	NULL
cell	NULL
survival	NULL
without	NULL
completely	NULL
blocking	NULL
granulocytic	NULL
differentiation	NULL
.	NULL

Discussion	NULL
Although	NULL
Bcl-2	NULL
was	NULL
expressed	NULL
at	NULL
elevated	NULL
levels	NULL
in	NULL
leukemic	NULL
cell	NULL
lines	NULL
synthesizing	NULL
AMLI/ETO	NULL
or	NULL
B/	NULL
SMMHC	NULL
,	NULL
over-expression	NULL
of	NULL
exogenous	NULL
Bcel-2	NULL
,	NULL
even	NULL
at	NULL
very	NULL
high	NULL
levels	NULL
,	NULL
did	NULL
not	NULL
completely	NULL
block	NULL
G-CSF	NULL
induction	NULL
of	NULL
the	NULL
granulocytic	NULL
differentiation	NULL
of	NULL
the	NULL
murine	NULL
myeloid	NULL
progenitor	NULL
cell	NULL
line	NULL
,	NULL
32Dcl3	NULL
.	NULL

This	NULL
is	NULL
in	NULL
contrast	NULL
to	NULL
AML1I/ETO	NULL
which	NULL
was	NULL
able	NULL
to	NULL
completely	NULL
block	NULL
the	NULL
differentiation	NULL
of	NULL
these	NULL
cells	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
major	NULL
target	NULL
of	NULL
AML1I/ETO	NULL
is	NULL
unlikely	NULL
to	NULL
be	NULL
upregulation	NULL
of	NULL
Bcel-2	NULL
,	NULL
although	NULL
upregulation	NULL
of	NULL
Bcl-2	NULL
would	NULL
contribute	NULL
to	NULL
leukemogenesis	NULL
by	NULL
increasing	NULL
resistance	NULL
to	NULL
cell	NULL
death	NULL
.	NULL

Earlier	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
overexpression	NULL
of	NULL
Bcl-2	NULL
has	NULL
little	NULL
or	NULL
no	NULL
effect	NULL
on	NULL
cell	NULL
differentiation	NULL
or	NULL
proliferation	NULL
(	NULL
Vaux	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Nunez	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

Despite	NULL
these	NULL
reports	NULL
,	NULL
expression	NULL
of	NULL
Bcel-2	NULL
was	NULL
shown	NULL
to	NULL
be	NULL
stimulated	NULL
by	NULL
AMLI/ETO	NULL
,	NULL
implying	NULL
that	NULL
stimulation	NULL
of	NULL
Bcl-2	NULL
expression	NULL
is	NULL
one	NULL
factor	NULL
in	NULL
the	NULL
Inability	NULL
of	NULL
Bcl-2	NULL
to	NULL
block	NULL
differentiation	NULL
of	NULL
32DcI13	NULL
H	NULL
Kohzaki	NULL
et	NULL
al	NULL
cl-9	NULL
we	NULL
*	NULL
$	NULL
3	NULL
s	NULL
fhe	NULL
%	NULL
Figure	NULL
5	NULL
-	NULL
May-Griinwald-Giemsa	NULL
staining	NULL
of	NULL
the	NULL
subclones	NULL
cl-9	NULL
and	NULL
cl-20	NULL
of	NULL
32D-Bcl2	NULL
.	NULL

(	NULL
a	NULL
)	NULL
and	NULL
(	NULL
b	NULL
)	NULL
:	NULL
c1-20	NULL
and	NULL
cl-9	NULL
,	NULL
respectively	NULL
,	NULL
in	NULL
IL-3	NULL
,	NULL
(	NULL
e	NULL
)	NULL
and	NULL
(	NULL
d	NULL
)	NULL
:	NULL
cl-20	NULL
and	NULL
cl-9	NULL
,	NULL
respectively	NULL
,	NULL
8	NULL
days	NULL
in	NULL
G-CSF	NULL
,	NULL
(	NULL
e	NULL
)	NULL
and	NULL
(	NULL
f	NULL
)	NULL
:	NULL
c1-20	NULL
and	NULL
cl-9	NULL
,	NULL
respectively	NULL
,	NULL
14	NULL
days	NULL
in	NULL
G-CSF	NULL
,	NULL
(	NULL
g	NULL
)	NULL
:	NULL
cl-9	NULL
,	NULL
20	NULL
days	NULL
in	NULL
G-CSF	NULL
leukemogenic	NULL
potential	NULL
of	NULL
this	NULL
chimeric	NULL
gene	NULL
(	NULL
Klampfer	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
Lin	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
also	NULL
reported	NULL
the	NULL
possibility	NULL
of	NULL
inhibition	NULL
of	NULL
differentiation	NULL
of	NULL
32Dcl3	NULL
cells	NULL
by	NULL
Bcl-2	NULL
.	NULL

For	NULL
the	NULL
induction	NULL
of	NULL
differentiation	NULL
,	NULL
however	NULL
,	NULL
they	NULL
removed	NULL
IL-3	NULL
.	NULL

Under	NULL
such	NULL
conditions	NULL
,	NULL
32Dcl3	NULL
cells	NULL
died	NULL
rapidly	NULL
and	NULL
only	NULL
a	NULL
small	NULL
portion	NULL
of	NULL
the	NULL
cells	NULL
(	NULL
5-20	NULL
%	NULL
)	NULL
showed	NULL
morphological	NULL
changes	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
after	NULL
replacement	NULL
of	NULL
IL-3	NULL
with	NULL
G-CSF	NULL
,	NULL
cells	NULL
continued	NULL
to	NULL
grow	NULL
for	NULL
several	NULL
days	NULL
and	NULL
virtually	NULL
all	NULL
of	NULL
the	NULL
cells	NULL
underwent	NULL
gross	NULL
morphological	NULL
changes	NULL
.	NULL

Thus	NULL
,	NULL
our	NULL
experimental	NULL
design	NULL
is	NULL
likely	NULL
to	NULL
reflect	NULL
more	NULL
closely	NULL
physiological	NULL
conditions	NULL
and	NULL
provide	NULL
a	NULL
better	NULL
basis	NULL
for	NULL
the	NULL
analysis	NULL
of	NULL
the	NULL
effect	NULL
of	NULL
Bel-2	NULL
.	NULL

Although	NULL
up-regulation	NULL
of	NULL
Bel-2	NULL
in	NULL
cell	NULL
lines	NULL
carrying	NULL
t	NULL
(	NULL
8	NULL
;	NULL
21	NULL
)	NULL
was	NULL
observed	NULL
in	NULL
the	NULL
present	NULL
study	NULL
,	NULL
the	NULL
question	NULL
still	NULL
remains	NULL
as	NULL
to	NULL
whether	NULL
primary	NULL
leukemic	NULL
cells	NULL
with	NULL
t	NULL
(	NULL
8	NULL
;	NULL
21	NULL
)	NULL
actually	NULL
express	NULL
higher	NULL
levels	NULL
of	NULL
Bel-2	NULL
in	NULL
vivo	NULL
.	NULL

Recently	NULL
,	NULL
Banker	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
reported	NULL
that	NULL
the	NULL
t	NULL
(	NULL
8	NULL
;	NULL
21	NULL
)	NULL
translocation	NULL
was	NULL
not	NULL
consistently	NULL
associated	NULL
with	NULL
high	NULL
Bcl-2	NULL
expression	NULL
in	NULL
de	NULL
novo	NULL
.	NULL

Earlier	NULL
,	NULL
Bcel-2	NULL
expression	NULL
was	NULL
reported	NULL
to	NULL
be	NULL
negatively	NULL
regulated	NULL
by	NULL
p53	NULL
8	NULL
Inability	NULL
of	NULL
Bcl-2	NULL
to	NULL
block	NULL
differentiation	NULL
of	NULL
32DcI13	NULL
H	NULL
Kohzaki	NULL
et	NULL
al	NULL
4060	NULL
(	NULL
Miyashita	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

Kampfer	NULL
et	NULL
al	NULL
.	NULL

,	NULL
(	NULL
1996	NULL
)	NULL
,	NULL
however	NULL
,	NULL
did	NULL
not	NULL
find	NULL
a	NULL
correlation	NULL
between	NULL
the	NULL
presence	NULL
of	NULL
p53	NULL
and	NULL
the	NULL
levels	NULL
of	NULL
Bel-2	NULL
expression	NULL
in	NULL
leukemic	NULL
cell	NULL
lines	NULL
.	NULL

In	NULL
the	NULL
most	NULL
recent	NULL
study	NULL
,	NULL
Banker	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
examined	NULL
the	NULL
p53	NULL
mutation	NULL
in	NULL
t	NULL
(	NULL
8	NULL
;	NULL
21	NULL
)	NULL
-bearing	NULL
cell	NULL
lines	NULL
as	NULL
well	NULL
as	NULL
in	NULL
primary	NULL
AML	NULL
cells	NULL
and	NULL
found	NULL
that	NULL
cell	NULL
lines	NULL
had	NULL
mutation	NULL
in	NULL
p53	NULL
but	NULL
primary	NULL
cells	NULL
did	NULL
not	NULL
.	NULL

Based	NULL
on	NULL
these	NULL
results	NULL
,	NULL
they	NULL
speculated	NULL
that	NULL
p53	NULL
mutations	NULL
may	NULL
contribute	NULL
to	NULL
higher	NULL
Bcl-2	NULL
expression	NULL
levels	NULL
in	NULL
leukemia	NULL
cell	NULL
lines	NULL
.	NULL

Although	NULL
further	NULL
studies	NULL
are	NULL
required	NULL
to	NULL
unequivocally	NULL
clarify	NULL
the	NULL
mechanisms	NULL
by	NULL
which	NULL
Bcl-2	NULL
expression	NULL
is	NULL
modified	NULL
by	NULL
AMLI/ETO	NULL
or	NULL
p53	NULL
in	NULL
primary	NULL
leukemic	NULL
cells	NULL
,	NULL
overall	NULL
conclusion	NULL
of	NULL
Banker	NULL
and	NULL
others	NULL
is	NULL
entirely	NULL
consistent	NULL
with	NULL
ours	NULL
obtained	NULL
in	NULL
the	NULL
current	NULL
study	NULL
.	NULL

Expression	NULL
of	NULL
AMLI/ETO	NULL
alone	NULL
is	NULL
not	NULL
considered	NULL
to	NULL
be	NULL
sufficient	NULL
to	NULL
convert	NULL
normal	NULL
myeloid	NULL
cells	NULL
to	NULL
leukemic	NULL
cells	NULL
,	NULL
since	NULL
some	NULL
patients	NULL
in	NULL
remission	NULL
have	NULL
cells	NULL
expressing	NULL
AMLI/ETO	NULL
.	NULL

Furthermore	NULL
,	NULL
transgenic	NULL
mice	NULL
containing	NULL
tetracyclin-inducible	NULL
AMLI/ETO	NULL
did	NULL
not	NULL
develop	NULL
leukemia	NULL
upon	NULL
induction	NULL
of	NULL
the	NULL
gene	NULL
in	NULL
the	NULL
myeloid	NULL
lineage	NULL
(	NULL
Don-Er	NULL
Zhang	NULL
,	NULL
personal	NULL
communica-tion	NULL
)	NULL
.	NULL

The	NULL
primary	NULL
event	NULL
induced	NULL
by	NULL
AMLI/ETO	NULL
might	NULL
be	NULL
upregulation	NULL
of	NULL
Bcel-2	NULL
,	NULL
even	NULL
if	NULL
over-expression	NULL
of	NULL
Bel-2	NULL
is	NULL
not	NULL
sufficient	NULL
to	NULL
induce	NULL
leukemia	NULL
.	NULL

However	NULL
,	NULL
as	NULL
summarized	NULL
above	NULL
,	NULL
the	NULL
phenotypes	NULL
of	NULL
32Dcl3	NULL
cells	NULL
over-expressing	NULL
Bcl-2	NULL
and	NULL
AML1I/ETO	NULL
are	NULL
so	NULL
different	NULL
that	NULL
this	NULL
interpretation	NULL
appears	NULL
unlikely	NULL
.	NULL

The	NULL
chimeric	NULL
protein	NULL
,	NULL
B/SMMHC	NULL
,	NULL
interacts	NULL
with	NULL
AML1	NULL
more	NULL
efficiently	NULL
than	NULL
the	NULL
normal	NULL
B	NULL
subunit	NULL
and	NULL
sequesters	NULL
AML1	NULL
to	NULL
the	NULL
cytoplasm	NULL
.	NULL

As	NULL
a	NULL
result	NULL
of	NULL
this	NULL
interaction	NULL
,	NULL
the	NULL
level	NULL
of	NULL
functional	NULL
PEBP2	NULL
is	NULL
presumed	NULL
to	NULL
be	NULL
insufficient	NULL
in	NULL
nuclei	NULL
,	NULL
resulting	NULL
in	NULL
deregulation	NULL
of	NULL
genes	NULL
under	NULL
the	NULL
control	NULL
of	NULL
PEBP2	NULL
(	NULL
Kanno	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

In	NULL
accordance	NULL
with	NULL
this	NULL
observation	NULL
,	NULL
B/SMMHC	NULL
severely	NULL
represses	NULL
promoter	NULL
activities	NULL
(	NULL
Liu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Kanno	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

It	NULL
is	NULL
interesting	NULL
to	NULL
note	NULL
that	NULL
ME-1	NULL
cells	NULL
expressing	NULL
B/SMMHC	NULL
express	NULL
Bcl-2	NULL
at	NULL
levels	NULL
even	NULL
higher	NULL
than	NULL
those	NULL
observed	NULL
in	NULL
Kasumi-1	NULL
and	NULL
SKNO-1	NULL
cells	NULL
.	NULL

If	NULL
the	NULL
molecular	NULL
mechanisms	NULL
of	NULL
upregulation	NULL
of	NULL
Bcl-2	NULL
by	NULL
AML1/ETO	NULL
and	NULL
B/SMMHC	NULL
are	NULL
the	NULL
same	NULL
,	NULL
we	NULL
must	NULL
consider	NULL
the	NULL
possibility	NULL
that	NULL
AMLI/ETO	NULL
stimulates	NULL
the	NULL
Bcl-2	NULL
promoter	NULL
by	NULL
derepressing	NULL
transcription	NULL
through	NULL
the	NULL
PEBP2	NULL
site	NULL
.	NULL

Detailed	NULL
studies	NULL
will	NULL
be	NULL
required	NULL
to	NULL
clarify	NULL
this	NULL
issue	NULL
.	NULL

Although	NULL
AML1I/ETO	NULL
stimulates	NULL
expression	NULL
of	NULL
Bel-2	NULL
by	NULL
acting	NULL
directly	NULL
on	NULL
the	NULL
regulatory	NULL
region	NULL
of	NULL
the	NULL
Bcl-2	NULL
gene	NULL
,	NULL
sustained	NULL
expression	NULL
of	NULL
Bcl-2	NULL
in	NULL
32D-AML1I/ETO	NULL
appears	NULL
to	NULL
be	NULL
due	NULL
to	NULL
a	NULL
different	NULL
mechanism	NULL
as	NULL
discussed	NULL
below	NULL
.	NULL

Over-expression	NULL
of	NULL
exogenous	NULL
Bcl-2	NULL
did	NULL
not	NULL
block	NULL
differentiation	NULL
of	NULL
32Dcl3	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
continuously	NULL
growing	NULL
32Dcl3	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
G-CSF	NULL
appeared	NULL
to	NULL
be	NULL
prevented	NULL
from	NULL
downregulating	NULL
Bcl-2	NULL
expression	NULL
.	NULL

As	NULL
discussed	NULL
above	NULL
,	NULL
the	NULL
reason	NULL
why	NULL
32Dcl3	NULL
cells	NULL
expressing	NULL
AMLI/ETO	NULL
were	NULL
able	NULL
to	NULL
grow	NULL
continuously	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
G-CSF	NULL
was	NULL
not	NULL
because	NULL
of	NULL
AMLI/ETO	NULL
induced	NULL
Bcel-2	NULL
expression	NULL
.	NULL

Rather	NULL
,	NULL
it	NULL
seems	NULL
possible	NULL
that	NULL
Bcl-2	NULL
expression	NULL
is	NULL
not	NULL
inhibited	NULL
in	NULL
such	NULL
cells	NULL
even	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
G-CSF	NULL
.	NULL

We	NULL
reported	NULL
earlier	NULL
that	NULL
Ear-2	NULL
,	NULL
a	NULL
member	NULL
of	NULL
the	NULL
orphan	NULL
nuclear	NULL
receptor	NULL
family	NULL
,	NULL
blocked	NULL
differentiation	NULL
of	NULL
32Dcl3	NULL
cells	NULL
and	NULL
that	NULL
cells	NULL
expressing	NULL
Ear-2	NULL
continued	NULL
to	NULL
grow	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
G-CSF	NULL
(	NULL
Ahn	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
we	NULL
observed	NULL
continuous	NULL
expression	NULL
of	NULL
Bel-2	NULL
in	NULL
32Dcl3	NULL
cells	NULL
expressing	NULL
Ear-2	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
G-CSF	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Parental	NULL
32Dc13	NULL
cells	NULL
use	NULL
G-CSF	NULL
as	NULL
a	NULL
differentiation	NULL
factor	NULL
but	NULL
both	NULL
AML1/ETO	NULL
and	NULL
Ear-2	NULL
are	NULL
able	NULL
to	NULL
induce	NULL
32Dc¢l3	NULL
cells	NULL
into	NULL
using	NULL
G-CSF	NULL
as	NULL
a	NULL
growth	NULL
factor	NULL
.	NULL

It	NULL
would	NULL
be	NULL
physiologically	NULL
meaningful	NULL
for	NULL
cells	NULL
to	NULL
continue	NULL
to	NULL
express	NULL
Bcl-2	NULL
during	NULL
growth	NULL
and	NULL
to	NULL
downregulate	NULL
Bcl-2	NULL
expression	NULL
during	NULL
differentiation	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
cells	NULL
expressing	NULL
AMLI/ETO	NULL
may	NULL
have	NULL
acquired	NULL
the	NULL
ability	NULL
to	NULL
prevent	NULL
downregulation	NULL
of	NULL
Bel-2	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
G-CSF	NULL
by	NULL
the	NULL
mechanism	NULL
which	NULL
subverted	NULL
the	NULL
cells	NULL
into	NULL
interpreting	NULL
G-CSF	NULL
signals	NULL
as	NULL
those	NULL
of	NULL
a	NULL
growth	NULL
factor	NULL
.	NULL

From	NULL
this	NULL
point	NULL
of	NULL
view	NULL
,	NULL
the	NULL
continuous	NULL
expression	NULL
of	NULL
Bcl-2	NULL
in	NULL
32Dcl3	NULL
cells	NULL
expressing	NULL
AML1/	NULL
ETO	NULL
could	NULL
still	NULL
be	NULL
a	NULL
consequence	NULL
of	NULL
the	NULL
function	NULL
of	NULL
AMLI/ETO	NULL
,	NULL
although	NULL
the	NULL
mechanism	NULL
is	NULL
completely	NULL
different	NULL
from	NULL
that	NULL
suggested	NULL
by	NULL
Klampfer	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

How	NULL
32Dcl3	NULL
cells	NULL
are	NULL
transformed	NULL
by	NULL
AMLI/ETO	NULL
to	NULL
read	NULL
signals	NULL
from	NULL
G-CSF	NULL
as	NULL
those	NULL
of	NULL
a	NULL
growth	NULL
factor	NULL
will	NULL
be	NULL
critically	NULL
important	NULL
for	NULL
our	NULL
understanding	NULL
of	NULL
the	NULL
mechanism	NULL
of	NULL
leukemogenesis	NULL
.	NULL

One	NULL
obstacle	NULL
to	NULL
our	NULL
hypothesis	NULL
that	NULL
a	NULL
loss	NULL
of	NULL
AML1	NULL
function	NULL
predisposes	NULL
to	NULL
leukemia	NULL
is	NULL
the	NULL
observed	NULL
AMLI/ETO	NULL
stimulation	NULL
of	NULL
Bel-2	NULL
expression	NULL
.	NULL

The	NULL
results	NULL
shown	NULL
in	NULL
this	NULL
paper	NULL
suggest	NULL
that	NULL
this	NULL
is	NULL
not	NULL
a	NULL
serious	NULL
obstacle	NULL
.	NULL

Stimulation	NULL
of	NULL
the	NULL
M-CSF	NULL
receptor	NULL
by	NULL
AML1I/ETO	NULL
needs	NULL
to	NULL
be	NULL
examined	NULL
in	NULL
more	NULL
detail	NULL
.	NULL

Materials	NULL
and	NULL
methods	NULL
Cells	NULL
and	NULL
culture	NULL
Murine	NULL
myelomonocytic	NULL
cell	NULL
line	NULL
,	NULL
WEHI-3B	NULL
,	NULL
(	NULL
Warner	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1969	NULL
)	NULL
and	NULL
human	NULL
myeloid	NULL
leukemia	NULL
cell	NULL
lines	NULL
,	NULL
Kasumi-1	NULL
(	NULL
Asou	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
and	NULL
SKNO-1	NULL
(	NULL
Matozaki	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
harboring	NULL
t	NULL
(	NULL
8	NULL
;	NULL
21	NULL
)	NULL
,	NULL
HL-60	NULL
(	NULL
Collins	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1977	NULL
;	NULL
Rovera	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1979	NULL
;	NULL
Breitmann	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1980	NULL
)	NULL
,	NULL
U937	NULL
(	NULL
Sundstrom	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1976	NULL
)	NULL
,	NULL
K562	NULL
(	NULL
Lozzio	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1975	NULL
)	NULL
and	NULL
ME-1	NULL
harboring	NULL
inv	NULL
(	NULL
16	NULL
)	NULL
(	NULL
Yanagisawa	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
were	NULL
grown	NULL
in	NULL
RPMI1640	NULL
medium	NULL
supplemented	NULL
with	NULL
20	NULL
%	NULL
(	NULL
Kasumi-1	NULL
)	NULL
or	NULL
10	NULL
%	NULL
(	NULL
HL-60	NULL
,	NULL
SKNO-1	NULL
,	NULL
ME-1	NULL
,	NULL
U937	NULL
,	NULL
K562	NULL
and	NULL
WEHI-3B	NULL
)	NULL
fetal	NULL
bovine	NULL
serum	NULL
(	NULL
culture	NULL
medium	NULL
,	NULL
CM	NULL
)	NULL
.	NULL

A	NULL
murine	NULL
interleukin-3	NULL
(	NULL
IL-3	NULL
)	NULL
dependent	NULL
myeloid	NULL
progenitor	NULL
cell	NULL
line	NULL
derived	NULL
from	NULL
normal	NULL
bone	NULL
marrow	NULL
long-term	NULL
culture	NULL
,	NULL
32Dcl3	NULL
(	NULL
Vailtieri	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
,	NULL
was	NULL
maintained	NULL
in	NULL
RPMI1640	NULL
containing	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
supplemented	NULL
with	NULL
5	NULL
%	NULL
WEHI-3B	NULL
culture	NULL
supernatant	NULL
as	NULL
a	NULL
source	NULL
of	NULL
IL-3	NULL
(	NULL
IL-3	NULL
medium	NULL
)	NULL
.	NULL

Plasmid	NULL
constructions	NULL
To	NULL
construct	NULL
the	NULL
mouse	NULL
Bel-2	NULL
expression	NULL
plasmid	NULL
,	NULL
pEF-BOSneoKR	NULL
,	NULL
the	NULL
Xhol	NULL
fragment	NULL
containing	NULL
the	NULL
coding	NULL
sequence	NULL
for	NULL
mouse	NULL
Bcl-2	NULL
from	NULL
pSKMBKR	NULL
(	NULL
obtained	NULL
from	NULL
M	NULL
Tsujimoto	NULL
of	NULL
Osaka	NULL
University	NULL
)	NULL
(	NULL
Negrini	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
and	NULL
pEF-BOSneo	NULL
(	NULL
Mizushima	NULL
er	NULL
a/	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
digested	NULL
with	NULL
Xbal	NULL
were	NULL
blunt-ended	NULL
by	NULL
T4	NULL
DNA	NULL
polymerase	NULL
and	NULL
ligated	NULL
.	NULL

Establishment	NULL
of	NULL
32Dcl3	NULL
stable	NULL
transformants	NULL
32Dcl3	NULL
cells	NULL
(	NULL
5x	NULL
10°	NULL
)	NULL
were	NULL
washed	NULL
three	NULL
times	NULL
in	NULL
HeBS	NULL
(	NULL
HEPES-buffered	NULL
saline	NULL
,	NULL
pH	NULL
7.05	NULL
)	NULL
(	NULL
Ausubel	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
and	NULL
resuspended	NULL
in	NULL
280	NULL
ul	NULL
of	NULL
HeBS	NULL
.	NULL

Twenty	NULL
ug	NULL
of	NULL
pEF-BOSneoKR	NULL
or	NULL
pEF-BOSneo	NULL
in	NULL
20	NULL
ul	NULL
of	NULL
TE	NULL
was	NULL
mixed	NULL
with	NULL
the	NULL
cells	NULL
and	NULL
transferred	NULL
to	NULL
cuvettes	NULL
with	NULL
a	NULL
0.2	NULL
cm	NULL
gap	NULL
(	NULL
Bio-Rad	NULL
)	NULL
.	NULL

Electroporation	NULL
was	NULL
performed	NULL
using	NULL
a	NULL
Gene	NULL
Pulser	NULL
(	NULL
Bio-Rad	NULL
)	NULL
at	NULL
270	NULL
V	NULL
,	NULL
960	NULL
uF	NULL
.	NULL

Samples	NULL
were	NULL
transferred	NULL
to	NULL
the	NULL
IL-3	NULL
medium	NULL
and	NULL
incubated	NULL
.	NULL

Forty-eight	NULL
hours	NULL
later	NULL
,	NULL
G418	NULL
(	NULL
GIBCO	NULL
)	NULL
was	NULL
added	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
0.6	NULL
mg/ml	NULL
.	NULL

Clones	NULL
of	NULL
stable	NULL
transfectants	NULL
were	NULL
selected	NULL
by	NULL
limiting	NULL
dilution	NULL
.	NULL

The	NULL
isolation	NULL
of	NULL
AML1I/ETO	NULL
stable	NULL
transformants	NULL
was	NULL
described	NULL
previously	NULL
(	NULL
Ahn	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

Induction	NULL
of	NULL
differentiation	NULL
For	NULL
the	NULL
induction	NULL
of	NULL
granulocytic	NULL
differentiation	NULL
,	NULL
32Dcl3	NULL
or	NULL
its	NULL
derivatives	NULL
were	NULL
washed	NULL
twice	NULL
with	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
and	NULL
cultured	NULL
in	NULL
the	NULL
medium	NULL
containing	NULL
500	NULL
U/ml	NULL
of	NULL
recombinant	NULL
human	NULL
granulocyte	NULL
colony	NULL
stimulating	NULL
factor	NULL
(	NULL
rhG-CSF	NULL
)	NULL
(	NULL
Kirin	NULL
Beer	NULL
,	NULL
Japan	NULL
)	NULL
.	NULL

The	NULL
medium	NULL
was	NULL
changed	NULL
every	NULL
2	NULL
days	NULL
with	NULL
fresh	NULL
G-CSF	NULL
.	NULL

For	NULL
morphological	NULL
examination	NULL
,	NULL
cells	NULL
were	NULL
washed	NULL
with	NULL
PBS	NULL
twice	NULL
and	NULL
deposited	NULL
onto	NULL
glass	NULL
slides	NULL
by	NULL
Cytospin	NULL
and	NULL
stained	NULL
with	NULL
May	NULL
-Griinwald-Giemsa	NULL
for	NULL
microscopic	NULL
examination	NULL
.	NULL

Cell	NULL
survival	NULL
assays	NULL
Cells	NULL
in	NULL
logarithmic	NULL
growth	NULL
phase	NULL
were	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
fresh	NULL
CM	NULL
with	NULL
no	NULL
added	NULL
cytokines	NULL
and	NULL
cultured	NULL
in	NULL
the	NULL
same	NULL
medium	NULL
in	NULL
triplicate	NULL
at	NULL
a	NULL
cell	NULL
density	NULL
of	NULL
4x	NULL
10°	NULL
cells/ml	NULL
.	NULL

The	NULL
number	NULL
of	NULL
viable	NULL
cells	NULL
was	NULL
determined	NULL
by	NULL
trypan	NULL
blue	NULL
staining	NULL
(	NULL
Rodel	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

Preparation	NULL
of	NULL
whole	NULL
cell	NULL
extracts	NULL
and	NULL
Western	NULL
blotting	NULL
Cells	NULL
(	NULL
5x	NULL
10°	NULL
)	NULL
were	NULL
pelleted	NULL
and	NULL
suspended	NULL
in	NULL
50	NULL
ul	NULL
of	NULL
SDS	NULL
sample	NULL
buffer	NULL
containing	NULL
62.2	NULL
mM	NULL
Tris-HCl	NULL
(	NULL
pH	NULL
6.8	NULL
)	NULL
,	NULL
50	NULL
mm	NULL
References	NULL
Ahn	NULL
MY	NULL
,	NULL
Huang	NULL
G	NULL
,	NULL
Bae	NULL
SC	NULL
,	NULL
Wee	NULL
HJ	NULL
,	NULL
Kim	NULL
WY	NULL
and	NULL
Ito	NULL
Y	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sei	NULL
.	NULL

USA	NULL
,	NULL
95	NULL
,	NULL
1812-1817	NULL
.	NULL

Asou	NULL
H	NULL
,	NULL
Tashiro	NULL
S	NULL
,	NULL
Hamamoto	NULL
K	NULL
,	NULL
Otsuji	NULL
A	NULL
,	NULL
Kita	NULL
K	NULL
and	NULL
Kamada	NULL
N.	NULL
(	NULL
1991	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
77	NULL
,	NULL
2031-2036	NULL
.	NULL

Ausubel	NULL
FM	NULL
,	NULL
Brent	NULL
R	NULL
,	NULL
Kingston	NULL
RE	NULL
,	NULL
Moore	NULL
DD	NULL
,	NULL
Seidman	NULL
JG	NULL
,	NULL
Smith	NULL
JA	NULL
and	NULL
Struhl	NULL
K.	NULL
(	NULL
1987	NULL
)	NULL
.	NULL

Current	NULL
Protocols	NULL
in	NULL
Molecular	NULL
Biology	NULL
.	NULL

Canada	NULL
,	NULL
Greene	NULL
Publishing	NULL
Associates	NULL
and	NULL
Wiley-Interscience	NULL
,	NULL
John	NULL
Wiley	NULL
&	NULL
Sons	NULL
.	NULL

Baffy	NULL
G	NULL
,	NULL
Miyashita	NULL
T	NULL
,	NULL
Williamson	NULL
JR	NULL
and	NULL
Reed	NULL
JC	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
268	NULL
,	NULL
6511-6519	NULL
.	NULL

Bakhshi	NULL
A	NULL
,	NULL
Jensen	NULL
JP	NULL
,	NULL
Goldman	NULL
P	NULL
,	NULL
Wright	NULL
JJ	NULL
,	NULL
McBride	NULL
OW	NULL
,	NULL
Epstein	NULL
EL	NULL
and	NULL
Korsmeyer	NULL
SJ	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
41	NULL
,	NULL
889-906	NULL
.	NULL

Banker	NULL
DE	NULL
,	NULL
Radish	NULL
J	NULL
,	NULL
Becker	NULL
A	NULL
,	NULL
Kerkof	NULL
K	NULL
,	NULL
Norwood	NULL
T	NULL
,	NULL
Willman	NULL
C	NULL
,	NULL
Appelbaum	NULL
FR	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
.	NULL

C/in	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
4	NULL
,	NULL
3051-3062	NULL
.	NULL

Breitmann	NULL
TR	NULL
,	NULL
Selonic	NULL
SE	NULL
and	NULL
Collins	NULL
SJ	NULL
.	NULL

(	NULL
1980	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Nat/	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
77	NULL
,	NULL
2936-2940	NULL
.	NULL

Cleary	NULL
ML	NULL
and	NULL
Sklar	NULL
J	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
82	NULL
,	NULL
7439-7443	NULL
.	NULL

Collins	NULL
SJ	NULL
,	NULL
Gallo	NULL
RC	NULL
and	NULL
Gallagher	NULL
RE	NULL
.	NULL

(	NULL
1977	NULL
)	NULL
.	NULL

Nature	NULL
,	NULL
270	NULL
,	NULL
347-352	NULL
.	NULL

Erickson	NULL
P	NULL
,	NULL
Gao	NULL
J	NULL
,	NULL
Chang	NULL
KS	NULL
,	NULL
Look	NULL
T	NULL
,	NULL
Whisenant	NULL
E	NULL
,	NULL
Raimondi	NULL
S	NULL
,	NULL
Lasher	NULL
J	NULL
,	NULL
Trujillo	NULL
J	NULL
,	NULL
Rowley	NULL
J	NULL
and	NULL
Drabkin	NULL
H.	NULL
(	NULL
1992	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
80	NULL
,	NULL
1825-1831	NULL
.	NULL

Fears	NULL
S	NULL
,	NULL
Gavin	NULL
M	NULL
,	NULL
Zhang	NULL
DE	NULL
,	NULL
Hetherington	NULL
C	NULL
,	NULL
Ben-David	NULL
Y	NULL
,	NULL
Rowley	NULL
JD	NULL
and	NULL
Nucifora	NULL
G.	NULL
(	NULL
1997	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Nat	NULL
!	NULL

.	NULL

Acad	NULL
.	NULL

Sei	NULL
.	NULL

USA	NULL
,	NULL
94	NULL
,	NULL
1949-1954	NULL
.	NULL

Frank	NULL
R	NULL
,	NULL
Zhang	NULL
J	NULL
,	NULL
Uchida	NULL
H	NULL
,	NULL
Meyers	NULL
S	NULL
,	NULL
Hiebert	NULL
SW	NULL
and	NULL
Nimer	NULL
SD	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Oncogene	NULL
,	NULL
11	NULL
,	NULL
2667-2674	NULL
.	NULL

Golub	NULL
TR	NULL
,	NULL
Barker	NULL
GF	NULL
,	NULL
Bohlaunder	NULL
SK	NULL
,	NULL
Hiebert	NULL
SW	NULL
,	NULL
Ward	NULL
DC	NULL
,	NULL
Bray-Ward	NULL
P	NULL
,	NULL
Morgan	NULL
E	NULL
,	NULL
Raimondi	NULL
SC	NULL
,	NULL
Rowley	NULL
JD	NULL
and	NULL
Gilliland	NULL
DG	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
92	NULL
,	NULL
4917-4921	NULL
.	NULL

Hiebert	NULL
SW	NULL
,	NULL
Sun	NULL
W	NULL
,	NULL
Davis	NULL
JN	NULL
,	NULL
Golub	NULL
T	NULL
,	NULL
Shurtleff	NULL
S	NULL
,	NULL
Buijs	NULL
A	NULL
,	NULL
Downing	NULL
J	NULL
,	NULL
Grosveld	NULL
G	NULL
,	NULL
Roussel	NULL
M	NULL
,	NULL
Gilliland	NULL
DG	NULL
,	NULL
Lenny	NULL
N	NULL
and	NULL
Meyers	NULL
S.	NULL
(	NULL
1996	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
16	NULL
,	NULL
1349-1355	NULL
.	NULL

Ito	NULL
K	NULL
,	NULL
Asano	NULL
M	NULL
,	NULL
Huge	NULL
P	NULL
,	NULL
Kohzaki	NULL
H	NULL
,	NULL
Masutani	NULL
C	NULL
,	NULL
Hanaoka	NULL
F	NULL
,	NULL
Kerppola	NULL
T	NULL
,	NULL
Curran	NULL
T	NULL
,	NULL
Murakami	NULL
Y	NULL
and	NULL
Ito	NULL
Y	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
15	NULL
,	NULL
5636-5646	NULL
.	NULL

Ito	NULL
Y	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

Clin	NULL
.	NULL

Oncol	NULL
.	NULL

,	NULL
122	NULL
,	NULL
266-274	NULL
.	NULL

Inability	NULL
of	NULL
Bcl-2	NULL
to	NULL
block	NULL
differentiation	NULL
of	NULL
32DcI13	NULL
H	NULL
Kohzaki	NULL
et	NULL
al	NULL
DTT	NULL
,	NULL
2	NULL
%	NULL
sodium	NULL
laurylsulfate	NULL
(	NULL
SDS	NULL
)	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
0.1	NULL
%	NULL
bromphenolblue	NULL
and	NULL
0.1	NULL
%	NULL
xylene	NULL
cyanol	NULL
,	NULL
sonicated	NULL
for	NULL
20	NULL
s	NULL
and	NULL
boiled	NULL
for	NULL
5	NULL
min	NULL
.	NULL

Ten	NULL
ul	NULL
of	NULL
each	NULL
cell	NULL
extract	NULL
was	NULL
subjected	NULL
to	NULL
15	NULL
%	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
(	NULL
PAGE	NULL
)	NULL
(	NULL
Ito	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
and	NULL
proteins	NULL
were	NULL
transferred	NULL
to	NULL
ImmobilonTM	NULL
(	NULL
MILLIPORE	NULL
)	NULL
.	NULL

Bel-2	NULL
protein	NULL
was	NULL
detected	NULL
by	NULL
anti-Bcl-2	NULL
monoclonal	NULL
antibody	NULL
(	NULL
Transduction	NULL
Laboratory	NULL
)	NULL
and	NULL
ECL	NULL
immunodetection	NULL
system	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

Bcl-2	NULL
protein	NULL
detected	NULL
by	NULL
Western	NULL
blotting	NULL
was	NULL
quantified	NULL
with	NULL
Quantity	NULL
one	NULL
(	NULL
PDI	NULL
,	NULL
Inc.	NULL
)	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
M	NULL
Tsujimoto	NULL
(	NULL
Osaka	NULL
University	NULL
)	NULL
,	NULL
H	NULL
Yamauchi	NULL
and	NULL
S	NULL
Fujita	NULL
(	NULL
Ehime	NULL
University	NULL
)	NULL
,	NULL
A	NULL
Friedman	NULL
(	NULL
Johns	NULL
Hopkins	NULL
University	NULL
)	NULL
and	NULL
T	NULL
Era	NULL
(	NULL
Osaka	NULL
University	NULL
)	NULL
for	NULL
Bcl-2	NULL
cDNA	NULL
(	NULL
pSKMBKR	NULL
)	NULL
,	NULL
ME-1	NULL
cells	NULL
,	NULL
32Dc13	NULL
cells	NULL
and	NULL
AML1/ETO	NULL
cDNA	NULL
,	NULL
respectively	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
Grant-in-Aid	NULL
0925322	NULL
for	NULL
Priority	NULL
Area	NULL
on	NULL
Cancer	NULL
Research	NULL
from	NULL
the	NULL
Ministry	NULL
of	NULL
Education	NULL
,	NULL
Science	NULL
and	NULL
Culture	NULL
,	NULL
Japan	NULL
.	NULL

Ito	NULL
Y	NULL
and	NULL
Bae	NULL
SC	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

In	NULL
:	NULL
Cell	NULL
Cycle	NULL
Regulators	NULL
and	NULL
Chromosomal	NULL
Translocation	NULL
,	NULL
(	NULL
eds	NULL
)	NULL
Yaniv	NULL
M	NULL
and	NULL
Ghysdael	NULL
J	NULL
,	NULL
Birkhauser	NULL
:	NULL
Basel	NULL
,	NULL
Vol	NULL
.	NULL

2	NULL
,	NULL
pp	NULL
.	NULL

107-132	NULL
.	NULL

Kanno	NULL
Y	NULL
,	NULL
Kanno	NULL
T	NULL
,	NULL
Sakakura	NULL
C	NULL
,	NULL
Bae	NULL
SC	NULL
and	NULL
Ito	NULL
Y	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
18	NULL
,	NULL
4252-4261	NULL
.	NULL

Kinashi	NULL
T	NULL
,	NULL
Lee	NULL
KH	NULL
,	NULL
Ogawa	NULL
M	NULL
,	NULL
Tohyama	NULL
K	NULL
,	NULL
Tashiro	NULL
K	NULL
,	NULL
Fukunaga	NULL
R	NULL
,	NULL
Nagata	NULL
S	NULL
and	NULL
Honjo	NULL
K.	NULL
(	NULL
1991	NULL
)	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
173	NULL
,	NULL
1267-1279	NULL
.	NULL

Kitabayashi	NULL
I	NULL
,	NULL
Ida	NULL
K	NULL
,	NULL
Morohoshi	NULL
F	NULL
,	NULL
Yokoyama	NULL
A	NULL
,	NULL
Mitsuhashi	NULL
N	NULL
,	NULL
Shimizu	NULL
K	NULL
,	NULL
Nomura	NULL
N	NULL
,	NULL
Hayashi	NULL
Y	NULL
and	NULL
Ohki	NULL
M.	NULL
(	NULL
1998	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
18	NULL
,	NULL
846-858	NULL
.	NULL

Klampfer	NULL
L	NULL
,	NULL
Zhang	NULL
J	NULL
,	NULL
Zelenetz	NULL
AO	NULL
,	NULL
Uchida	NULL
H	NULL
and	NULL
Nimer	NULL
SD	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
93	NULL
,	NULL
14059-14064	NULL
.	NULL

Lin	NULL
EY	NULL
,	NULL
Orlofsky	NULL
A	NULL
,	NULL
Wang	NULL
HG	NULL
,	NULL
Reed	NULL
JC	NULL
and	NULL
Prystowsky	NULL
MB	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
87	NULL
,	NULL
983-992	NULL
.	NULL

Liu	NULL
PP	NULL
,	NULL
Siedel	NULL
N	NULL
,	NULL
Bodine	NULL
D	NULL
,	NULL
Speck	NULL
NA	NULL
,	NULL
Tarle	NULL
S	NULL
and	NULL
Collins	NULL
FS	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

CSH	NULL
Symp	NULL
.	NULL

Quant	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
59	NULL
,	NULL
547-553	NULL
.	NULL

Liu	NULL
PP	NULL
,	NULL
Tarle	NULL
SA	NULL
,	NULL
Hajra	NULL
A	NULL
,	NULL
Claxton	NULL
DF	NULL
,	NULL
Marlton	NULL
P	NULL
,	NULL
Freedman	NULL
M	NULL
,	NULL
Siciliano	NULL
MJ	NULL
and	NULL
Collins	NULL
FS	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

Science	NULL
,	NULL
261	NULL
,	NULL
1041-1044	NULL
.	NULL

Look	NULL
AT	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

Science	NULL
,	NULL
278	NULL
,	NULL
1059-1064	NULL
.	NULL

Lozzio	NULL
CB	NULL
and	NULL
Lozzio	NULL
BB	NULL
.	NULL

(	NULL
1975	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
45	NULL
,	NULL
321-330	NULL
.	NULL

Lu	NULL
J	NULL
,	NULL
Maruyama	NULL
M	NULL
,	NULL
Satake	NULL
M	NULL
,	NULL
Bae	NULL
SC	NULL
,	NULL
Ogawa	NULL
E	NULL
,	NULL
Kagoshima	NULL
H	NULL
,	NULL
Shigesada	NULL
K	NULL
and	NULL
Ito	NULL
Y	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
15	NULL
,	NULL
1651-1661	NULL
.	NULL

Matozaki	NULL
S	NULL
,	NULL
Nakagawa	NULL
T	NULL
,	NULL
Kawaguchi	NULL
R	NULL
,	NULL
Aozaki	NULL
R	NULL
,	NULL
Tsutsumi	NULL
M	NULL
,	NULL
Maruyama	NULL
T	NULL
,	NULL
Koizumi	NULL
T	NULL
,	NULL
Nishimura	NULL
R	NULL
,	NULL
Isobe	NULL
T	NULL
and	NULL
Chihara	NULL
K.	NULL
(	NULL
1995	NULL
)	NULL
.	NULL

Br	NULL
.	NULL

J	NULL
.	NULL

Haemotol	NULL
.	NULL

,	NULL
89	NULL
,	NULL
805	NULL
811	NULL
.	NULL

Meyers	NULL
S	NULL
,	NULL
Lenny	NULL
N	NULL
and	NULL
Hiebert	NULL
SW.	NULL
(	NULL
1995	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
15	NULL
,	NULL
1974-1982	NULL
.	NULL

Meyers	NULL
S	NULL
,	NULL
Lenny	NULL
N	NULL
,	NULL
Sun	NULL
W	NULL
and	NULL
Hiebert	NULL
SW.	NULL
(	NULL
1996	NULL
)	NULL
.	NULL

Oncogene	NULL
,	NULL
13	NULL
,	NULL
303-312	NULL
.	NULL

Mitani	NULL
K	NULL
,	NULL
Ogawa	NULL
S	NULL
,	NULL
Tanaka	NULL
T	NULL
,	NULL
Miyoshi	NULL
H	NULL
,	NULL
Kurokawa	NULL
M	NULL
,	NULL
Mano	NULL
H	NULL
,	NULL
Yazaki	NULL
Y	NULL
,	NULL
Ohki	NULL
M	NULL
and	NULL
Hirai	NULL
H.	NULL
(	NULL
1994	NULL
)	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
13	NULL
,	NULL
504-510	NULL
.	NULL

Miyashita	NULL
T	NULL
,	NULL
Harigai	NULL
M	NULL
,	NULL
Hanada	NULL
M	NULL
and	NULL
Reed	NULL
JC	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
54	NULL
,	NULL
3131-3135	NULL
.	NULL

4061	NULL
Inability	NULL
of	NULL
Bcl-2	NULL
to	NULL
block	NULL
differentiation	NULL
of	NULL
32DcI13	NULL
H	NULL
Kohzaki	NULL
et	NULL
al	NULL
4062	NULL
Miyoshi	NULL
H	NULL
,	NULL
Shimizu	NULL
K	NULL
,	NULL
Kozu	NULL
T	NULL
,	NULL
Maseki	NULL
N	NULL
,	NULL
Kaneko	NULL
Y	NULL
and	NULL
Ohki	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
88	NULL
,	NULL
10431	NULL
10434	NULL
.	NULL

Miyoshi	NULL
H	NULL
,	NULL
Kozu	NULL
T	NULL
,	NULL
Shimizu	NULL
K	NULL
,	NULL
Enomoto	NULL
K	NULL
,	NULL
Maseki	NULL
N	NULL
,	NULL
Kaneko	NULL
Y	NULL
,	NULL
Kamada	NULL
N	NULL
and	NULL
Ohki	NULL
M.	NULL
(	NULL
1993	NULL
)	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
12	NULL
,	NULL
2715-2721	NULL
.	NULL

Mizushuma	NULL
S	NULL
and	NULL
Nagata	NULL
S.	NULL
(	NULL
1990	NULL
)	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

,	NULL
18	NULL
,	NULL
5322	NULL
.	NULL

Negrini	NULL
M	NULL
,	NULL
Silini	NULL
E	NULL
,	NULL
Kozak	NULL
C	NULL
,	NULL
Tsujimoto	NULL
Y	NULL
and	NULL
Croce	NULL
CM	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
49	NULL
,	NULL
455-463	NULL
.	NULL

Nucifora	NULL
G	NULL
,	NULL
Begy	NULL
CR	NULL
,	NULL
Erikson	NULL
P	NULL
,	NULL
Drabkin	NULL
HA	NULL
and	NULL
Rowley	NULL
JD	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sei	NULL
.	NULL

USA	NULL
,	NULL
90	NULL
,	NULL
7784-7788	NULL
.	NULL

Nucifora	NULL
G	NULL
,	NULL
Begy	NULL
CR	NULL
,	NULL
Kobayashi	NULL
H	NULL
,	NULL
Roulston	NULL
D	NULL
,	NULL
Claxton	NULL
D	NULL
,	NULL
Pedersen-Bjergaard	NULL
J	NULL
,	NULL
Parganas	NULL
E	NULL
,	NULL
Ihle	NULL
JN	NULL
and	NULL
Rowely	NULL
JD	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sei	NULL
.	NULL

USA	NULL
,	NULL
91	NULL
,	NULL
4004-4008	NULL
.	NULL

Nucifora	NULL
G	NULL
and	NULL
Rowely	NULL
JD	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
86	NULL
,	NULL
1-14	NULL
.	NULL

Nunez	NULL
G	NULL
,	NULL
London	NULL
L	NULL
,	NULL
Hockenbery	NULL
D	NULL
,	NULL
Alexander	NULL
M	NULL
,	NULL
Mckearn	NULL
JP	NULL
and	NULL
Korsmeyer	NULL
SJ	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
.	NULL

J	NULL
.	NULL

Immnol	NULL
.	NULL

,	NULL
144	NULL
,	NULL
3602-3610	NULL
.	NULL

Okada	NULL
H	NULL
,	NULL
Watanabe	NULL
T	NULL
,	NULL
Niki	NULL
M	NULL
,	NULL
Takano	NULL
H	NULL
,	NULL
Chiba	NULL
N	NULL
,	NULL
Yanai	NULL
N	NULL
,	NULL
Tani	NULL
K	NULL
,	NULL
Hibino	NULL
H	NULL
,	NULL
Asano	NULL
S	NULL
,	NULL
Mucenski	NULL
ML	NULL
,	NULL
Ito	NULL
Y	NULL
,	NULL
Noda	NULL
T	NULL
and	NULL
Satake	NULL
M.	NULL
(	NULL
1998	NULL
)	NULL
.	NULL

Oncogene	NULL
,	NULL
17	NULL
,	NULL
2287-2293	NULL
.	NULL

Okuda	NULL
T	NULL
,	NULL
Deursen	NULL
JV	NULL
,	NULL
Hiebert	NULL
SW	NULL
,	NULL
Grosveld	NULL
G	NULL
and	NULL
Downing	NULL
JR.	NULL
(	NULL
1996	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
84	NULL
,	NULL
321-330	NULL
.	NULL

Osato	NULL
M	NULL
,	NULL
Asou	NULL
N	NULL
,	NULL
Abdalla	NULL
E	NULL
,	NULL
Hoshino	NULL
K	NULL
,	NULL
Yamasaki	NULL
H	NULL
,	NULL
Okubo	NULL
T	NULL
,	NULL
Suzushima	NULL
H	NULL
,	NULL
Takatsuki	NULL
K	NULL
,	NULL
Kanno	NULL
T	NULL
,	NULL
Shigesada	NULL
K	NULL
and	NULL
Ito	NULL
Y	NULL
.	NULL

(	NULL
1999	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
in	NULL
press	NULL
.	NULL

Reed	NULL
JC	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
124	NULL
,	NULL
1-6	NULL
.	NULL

Rodel	NULL
JE	NULL
and	NULL
Link	NULL
DC	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
87	NULL
,	NULL
858-864	NULL
.	NULL

Romana	NULL
SP	NULL
,	NULL
Mauchauffle	NULL
M	NULL
,	NULL
Coniat	NULL
ML	NULL
,	NULL
Chumakov	NULL
I	NULL
,	NULL
Paslier	NULL
DL	NULL
,	NULL
Berger	NULL
R	NULL
and	NULL
Bernard	NULL
OA	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
85	NULL
,	NULL
3662-3670	NULL
.	NULL

Rhoades	NULL
K	NULL
,	NULL
Hetherington	NULL
CJ	NULL
,	NULL
Rowley	NULL
JD	NULL
,	NULL
Hiebert	NULL
SW	NULL
,	NULL
Nucifora	NULL
G	NULL
,	NULL
Tenen	NULL
DG	NULL
and	NULL
Zhang	NULL
DE	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sei	NULL
.	NULL

USA	NULL
,	NULL
93	NULL
,	NULL
11895-11900	NULL
.	NULL

Rovera	NULL
G	NULL
,	NULL
O'Brien	NULL
TG	NULL
and	NULL
Diamond	NULL
L.	NULL
(	NULL
1979	NULL
)	NULL
.	NULL

Science	NULL
,	NULL
204	NULL
,	NULL
868-870	NULL
.	NULL

Sasaki	NULL
K	NULL
,	NULL
Yagi	NULL
H	NULL
,	NULL
Bronson	NULL
RT	NULL
,	NULL
Tominaga	NULL
K	NULL
,	NULL
Matsunashi	NULL
T	NULL
,	NULL
Deguchi	NULL
K	NULL
,	NULL
Tani	NULL
Y	NULL
,	NULL
Kishimoto	NULL
T	NULL
and	NULL
Komori	NULL
T.	NULL
(	NULL
1996	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
93	NULL
,	NULL
12359-12363	NULL
.	NULL

Speck	NULL
NA	NULL
and	NULL
Stacy	NULL
T.	NULL
(	NULL
1995	NULL
)	NULL
.	NULL

Critical	NULL
Reviews	NULL
in	NULL
Eukaryotic	NULL
Gene	NULL
Expression	NULL
,	NULL
5	NULL
,	NULL
pp	NULL
.	NULL

337-364	NULL
.	NULL

Sundstrom	NULL
C	NULL
and	NULL
Nilsson	NULL
K.	NULL
(	NULL
1976	NULL
)	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
17	NULL
,	NULL
565-577	NULL
.	NULL

Tanaka	NULL
T	NULL
,	NULL
Mitani	NULL
K	NULL
,	NULL
Kurokawa	NULL
M	NULL
,	NULL
Ogawa	NULL
S	NULL
,	NULL
Tanaka	NULL
K	NULL
,	NULL
Nishida	NULL
J	NULL
,	NULL
Yazaki	NULL
Y	NULL
,	NULL
Shibata	NULL
Y	NULL
and	NULL
Hirai	NULL
H.	NULL
(	NULL
1995	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
15	NULL
,	NULL
2383-2392	NULL
.	NULL

Tsujimoto	NULL
Y	NULL
,	NULL
Gorham	NULL
J	NULL
,	NULL
Cossman	NULL
J	NULL
,	NULL
Jaffe	NULL
E	NULL
and	NULL
Croce	NULL
CM	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
.	NULL

Science	NULL
,	NULL
229	NULL
,	NULL
1390-1393	NULL
.	NULL

Uchida	NULL
H	NULL
,	NULL
Zhang	NULL
J	NULL
and	NULL
Nimer	NULL
SD	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
158	NULL
,	NULL
2251-2258	NULL
.	NULL

Valtieri	NULL
M	NULL
,	NULL
Tweardy	NULL
DJ	NULL
,	NULL
Caracciolo	NULL
D	NULL
,	NULL
Johnson	NULL
K	NULL
,	NULL
Mavilio	NULL
F	NULL
,	NULL
Altmann	NULL
S	NULL
,	NULL
Santoli	NULL
D	NULL
and	NULL
Rovera	NULL
G.	NULL
(	NULL
1987	NULL
)	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
138	NULL
,	NULL
3829-3835	NULL
.	NULL

Vaux	NULL
DL	NULL
,	NULL
Cory	NULL
S	NULL
and	NULL
Adams	NULL
JM	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
.	NULL

Nature	NULL
,	NULL
335	NULL
,	NULL
440	NULL
442	NULL
.	NULL

Wang	NULL
Q	NULL
,	NULL
Stacy	NULL
T	NULL
,	NULL
Binder	NULL
M	NULL
,	NULL
Marin-Padilla	NULL
M	NULL
,	NULL
Sharpe	NULL
AH	NULL
and	NULL
Speck	NULL
NA	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
93	NULL
,	NULL
3444-3449	NULL
.	NULL

Warner	NULL
NL	NULL
,	NULL
Moore	NULL
MAS	NULL
and	NULL
Metcalf	NULL
D.	NULL
(	NULL
1969	NULL
)	NULL
.	NULL

J.	NULL
Natl	NULL
.	NULL

Cancer	NULL
Inst	NULL
.	NULL

,	NULL
43	NULL
,	NULL
963-982	NULL
.	NULL

Yanagisawa	NULL
K	NULL
,	NULL
Horiuchi	NULL
T	NULL
and	NULL
Fujita	NULL
S.	NULL
(	NULL
1991	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
78	NULL
,	NULL
451-457	NULL
.	NULL

